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PREVALENCE OF THYROID DYSFUNCTION IN ADULT HIV PATIENTS ON 
HAART IRRESPECTIVE OF STAGING AND CORRELATION BETWEEN THE 
TSH AND CD-4 COUNT 
AUTHOR: Dr. Karthik P     GUIDE: Prof. S. Rajasekaran M.D. 
ABSTRACT 
OBJECTIVE: 
 This study was done to know the prevalence of thyroid dysfunction in adult HIV 
patients on HAART irrespective of staging and correlation between the TSH and CD-4 count. 
METHODOLOGY: 
Patient attending ART centre in madras medical college in RGGGH are included in 
the study. Questionnaire and clinical examination was done and free T3, T4, TSH and CD-4 
count was done. Sample size is 100. Study period is 6 months APRIL – 2014 to 
SEPTEMBER – 2014.  
RESULTS: 
 The prevalence of thyroid dysfunction in our study is 11% (11 out of 100 patients). 
Overt hypothyroidism – 2%, subclinical hypothyroidism – 9%. 8 patients are male sex and 
CD-4 count less than 200. There is significant negative correlation between CD-4 count and 
TSH (Pearson Chi-Square p value .000). 
CONCLUSION: 
There is increased prevalence of thyroid dysfunction in HIV patients on HAART 
especially male sex, low CD-4 count and longer duration of disease. 
KEY WORDS: HIV, HAART, TSH, CD-4 
 1 
INTRODUCTION 
HIV   [human  immuno deficiency  virus ]   the   etiological   
agent  of   AIDS.  Two types  HIV virus  HIV 1  and HIV  2  which  
causes    cytopathic  effects   either  directly  or  indirectly  .  
The   various  spectrum of  endocrine  dysfunctions    
manifested  in  patients  with    HIV   are  related  directly  to  virus   
or   secondary  to    opportunistic   infections,   drugs,   malignancy   
and    mainly    affects   ADRENAL  GLAND,   GONADS,   
THYROID,  PITUTARY. 
Thyroid   Dysfunction   is   a   recognized   entity   in   HIV   
infection. 
Thyroid   function alteration   seen   in    up to   10   to  15%   
of  HIV  patients. 
The predominant abnormality is sub clinical  hypothyroidism   
but   both   overt   hypothyroidism  and   hyperthyroidism  may  
occur    in   HIV   infected  patients.  
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PATTERN OF THYROID ABNORMALITY  IN  HIV  PATIENTS     
Sub clinical  hypothyroidism 
Overt  hypothyroidism 
Hyperthyroidism  [subclinical / overt] 
Immune   reconstitution  Graves   disease.  
The   dysfunctions    may  caused   by    direct   effects   of   
HIV    on  thyroid   gland  or  due to   opportunistic  infections  that  
occurs  in  HIV  patients, or  neoplasm  .  
The  risk  factor   for   development  of  thyroid  dysfunctions  
in  HIV  patients  are    
 Low  CD4  count 
 Male  sex 
 Longer  duration  of  disease 
 HAART. 
 Advanced  disease 
In the  setting  of  HAART    ,  up to  10%  of  patients    have  
elevated  TSH  may  a  manifestations  of   immune  reconstitution .  
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Immune   reconstitution   grave s   disease   may  be  occur   
as   a  late  complication  of  HAART. 
The   various  studies   shows  that   TSH   level   negatively  
correlates  with  CD4 count,   and   abnormalities   in  thyroid    
function  may   used  as   surrogate  marker  of   advancing   HIV  
infection  in  infected  adults.  
In  this   study   100   HIV  infected    adult  patients,   aged   
above   18  years   are  studied about  symptoms related  to  thyroid  
dysfunctions  and  TFT   and  CD4   count  measured   . 
The   prevalence  of  thyroid  dysfunction   and   correlation 
between  TSH    and   CD4  count    analyzed.  
It  is  important   to   evaluate   thyroid  function  in  HIV  
patients   because   various  studies   shows  a  higher  than   
expected   incidence   of  overt    hypothyroidism   found  in   
patient  receive  HAART.  
Recommends   universal  screening  of   thyroid  function  in  
HIV  patients   on  HAART  especially  in  symptomatic  and   
patients  with  risk  factor  for  developing  thyroid  dysfunction.  
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AIMS   AND   OBJECTIVES 
The  study    was    done   to  know   the    prevalence  of  
thyroid    dysfunction   in    adult   hiv  patients  on  highly  active  
anti retro viral therapy irrespective  of  stage  of  disease   and   
find  out  the   correlation  between   TSH  level   and   CD4  count.  
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REVIEW OF LITERATURE 
HISTORY
 [1]
 
HIV belongs to family Retrovirus   and  sub family  Lenti 
virus.    HIV was first recognized at USA among homosexual men 
on 1981 and the virus was first isolated from patients with  
lymphadenopathy in 1983.  The initial reporting  manifestations  
were   P.jiroveci  pneumonia  and  Kaposi‟s sarcoma.  It has spread 
all over the world.    HIV is the causative agent of AIDS and 
demonstrated at 1984. In 1985 the sensitive  Diagnostic  met hod 
ELISA developed. HIV infection was first detected in India in 
1986, among female sex workers in Chennai.  NACO launched the 
Highly Active Anti Retroviral Therapy (HAART), in the form of 
fixed drug combinations on April 2004. [2]   The most common mode 
of spread is heterosexual.   
Global summary of the AIDS epidemics as on December 2012 
[3]
  
Number of people living With HIV  at the end of  2012  
 Total  35.3 million (32.2 -  38.8  million 
 Women 17.7 million (16.4 – 19.3.million) 
People newly infected with HIV  at the end of 2012 
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 Total  2.3  million (1.9 – 2.7 million) 
AIDS deaths  at the end of 2012  
 Total  1.6 million (1.4  – 1.9  million 
The sub Saharan Africa remains the most severly affected in 
worldwide, approximately 1 in every 20 adults  living with h iv. 
And accounts for 71% of HIV infection patients worldwide.  
IN INDIA
[4]
 
Number of people living with HIV in india – 2.4 million [1.93 – 3.04]. 
Male                    - 61% 
Female                      - 39% 
Children < 14 yrs     - 4.4% 
Age 15 – 49 yrs       - 82.4% 
Over 50 yrs             - 13.2%  
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                STRUCTURE OF HIV-1 
 
 “The gp120 envelope, gp41 transmembrane components of 
the envelope, genomic RNA, enzymereverse transcriptase, p18(17) 
inner membrane (matrix), and p24 core protein (caps id)” 
ETIOLOGIC AGENT 
HIV-1  and  HIV-2  both  cause  cytopathic effects  either 
directly  or  indirectly  .. 
HIV-1 is the most common cause  in world wide..  
HIV-2 first identified  in 1986 and  originally confined  to 
west Africa. 
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Currently  defined groups  of HIV-  1 [ M, N,  O,  P] ,  HIV  - 
2 [A through  G],  each  likely  derived from a separate transfer  to 
humans  from  non human  primates. 
           Binding and fusion of HIV-1 with its target cell 
 
“HIV-1 binds to its target cell via the CD4 molecule, leading 
to a conformational change in the gp120 molecule that allows it to 
bind to the co-receptor CCR5 (for R5-using viruses). The virus then 
firmly attaches to the host cell membrane in a coiled-spring fashion 
via the newly exposed gp41 molecule. Virus-cell fusion occurs as 
the transitional intermediate of gp41 undergoes further changes to 
form a hairpin structure that draws the two membranes into close 
proximity” 
 9 
MORPHOLOGY OF HIV
[5, 6] 
From the antigenic point of view, we can group HIV structure 
into: 
Envelop 
Main component for binding to CD4+ T cells. 
Principal antigens are – gp41, gp120. 
Nucleocapsid consists of: 
Outer icosahedral shell – Principal antigen is   p18 (shell 
antigen). 
Inner cone shaped core – core antigens – p24 (principal 
antigen) Other – P15, P35. 
RNA  
Constitutes the genome  
Polymerase antigens – p31, p51, p66   
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                                  HIV Genome 
 
Figure-3 illustrates schematically the arrangement of the 
HIV genome.   The major difference between the genomes of HIV-1 
and HIV-2 is the fact that HIV-2 lacks the vpu gene and has a vpx 
gene not contained in HIV-1 
VIRAL GENOME 
The genome contains the  three  structural    genes and other   
nonstructural genes and  regulatory genes  specific for virus.  
The products of structural and nonstructural genes acts as 
antigens, sera of infected persons have antibodies to them and 
detection of these antigen and antibodies useful in diagnosis and 
prognosis of HIV infection.  
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STRUCTURAL GENES 
1.GAG genes-determine the core and shell of the virus .It  
Expressed as  a precursor  protein P 55  cleaved  into three proteins  
which make up viral  core  and shell. [P15, P18, P24].  
The major core antigen is P24 ,it can be detected in early 
stage of HIV infection  before antibodies to appear.  
2. ENV – synthesis of envelope GP 160  which cleaved into  
gp120  the surface spike protein ,and  gp41  a transmembrane 
anchoring protein. 
Antibodies to gp 120are present in circulation till  the 
terminal stage of infection.  
3.PLO gene – codes  for  polymerase reverse transcriptase  
and other viral enzyme. 
HIV REPLICATION 
 The replication cycle  begins with  binding of gp120  via  V1  
region near  N terminus  to  its  receptor  on host cell surface, 
the CD4 molecule. 
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 The CD4  molecule  is a 55kDa  protein  found in 
predominantly helper T lymphocytes,  and also expressed  in  
monocytes , macrophage,  dentritic cell,  langerhans cell..  
 Once gp120 binds to CD4, the gp120 undergoes 
conformational changes  which facilitates  binding  to major 
co-receptor. 
 Following conformational  changes  gp120  fusion with  host 
cell membrane  via gp41 molecule penetrates the plasma 
membrane of target cell..  
 Then coiling upon itself  to bring the virion and target cell 
together  leads to formation of  preintegration complex   , 
composed  of  viral RNA   and  viral enzymes, surrounded by 
a capsid  protein coat , is released into cytoplasm of cell.  
 The viral reverse transcriptase enzyme catalyzes the  genomic  
RNA into DNA  and  protein coat opens  to release  the 
resulting  double standard  proviral HIV DNA. 
 Activation of cell -  The viral DNA integrated to the host cell  
chromosomes  through  integrase enzyme..and  HIV proviral 
DNA integrates into nuclear DNA preferentially within 
introns of active genes and regional hot spots.  
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 The provirus may remain transcriptionally inactive [latent]  or  
may  manifest varying level  of gene expression up to  active 
production of virus..    
GLOBAL VARIATIONS OF HIV-1 
 
 
Geographic distribution of HIV-1 subtypes and  
recombinant forms 
 
ORIGIN OF THE HIV EPIDEMIC 
Molecular phylogenetic studies suggest that HIV evolved 
from simian immunodeficiency virus (SIV), which has been found 
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in two of four subspecies of chimpanzees in the Cameroon [7].  HIV 
has evolved into groups M, N and O; M (“Main”) is considered the 
pandemic strain and comprises the vast majority of strains of HIV.  
Viruses from group M are subsequently divided into ten distinct 
subtypes (A to J).  Group O (“Outlier”) represents far fewer strains 
from Cameroon, Gabon and Equatorial Guinea.  Group N  (“non-M / 
non-O”) is represented by very few isolates and has only been 
documented in Cameroon.  Studies have been performed to 
ascertain the origins of HIV infection.  Through sequence analysis, 
the origins of pandemic (group M) and nonpandemic (group N)  
HIV could be traced to isolate geographically chimpanzee 
communities
8
.  The origin of group O HIV is still unknown.  
CASE DEFINITION  - INDIA ( ABOVE 12 YEARS OF AGE) 
1) Two positive tests for HIV infection by ERS test 
(Elisa/Rapid/Simple) AND 
2) Any one -criteria 
a. Significant weight loss (>10% of body weight) within last 
1 month/cachexia (rather than HIV infection).   AND 
Chronic diarrhea (intermittent or continuous) >one month 
duration or prolonged fever (intermittent or continuous) 
>one month duration.   
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b. Tuberculosis: Extensive pulmonary, disseminated, 
milliary, extra-pulmonary tuberculosis.   
c. Neurological impairment preventing independent daily 
activities, not known to be due to the conditions unrelated 
to HIV infection (e.g. trauma) 
d. Candidiasis of the oesophagus (diagnosable by oral 
candidiasis by odynophagia) 
e. Clinically diagnosed life threatening or multiple episodes 
of pneumonia, with or without etiological confirmation.  
f. Kaposi Sarcoma 
g. Other conditions: 
i. Cryptococcal meningitis 
ii. Neuro Toxoplasmosis 
iii. CMV retinitis 
iv. P.marneffei 
v. Recurrent Herpes Zoster or multi-dermatomal herpes 
infection 
vi. Disseminated molluscum 
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DEFINITION 
 “The CDC classification system   This system is based on:  
1) Clinical conditions of HIV infection 
2) CD4+ count 
Confirmed  by Elisa and Western blot with CD4+ count 
<200/mm
3
 And / or 
Category-A   
 Asymptomatic HIV infection 
 Persistent generalized lymphadenopathy 
 Acute (Primary) HIV infection with accompanying illness or 
history of acute HIV infection.  
Category-B 
Consists of symptomatic conditions in an HIV-infected 
adolescent or adult that are not included among conditions listed in 
clinical category C and meet at least one of the following criteria:  
1) The conditions are attributed to HIV infection or are of a 
defect in cell-mediated immunity; or 
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2) The conditions are considered by physicians to have a clinical 
course or to require management and complicated by HIV 
infection.  Examples  
a. Bacilliary angiomatosis 
b. Candidiasis, oropharyngeal (thrush) 
c. Candidiasis, vulvovaginal; persistent, frequent, or poorly 
response to therapy. 
d. Cervical dysplasia (moderate or severe) /cervical carcinoma in situ. 
e. Constitutional symptoms, such as diarrhea lasting >1month 
or fever (38.5°C) . 
f. Hairy leukoplakia, 
g. Herpes zoster (shingles), involving at least two distinct 
pisodes or more than one dermatome. 
h. Idiopathic thrombocytopenic purpura 
i. Listeriosis 
j. Pelvic inflammatory disease,  if complicated by 
tuboovarian abscess. 
k. Peripheral neuropathy 
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CATEGORY C CONDITION 
1) Candidiasis of bronchi, trachea, lungs or esophagus  
2) Cervical cancer invasive 
3) Coccidioidomycosis disseminated or extra pulmonary 
4) Extra pulmonary Cryptococcosis ,  
5) Cryptosportidiosis- intestinal (>1 month) 
6) Cytomegalovirus disease other than spleen, liver, or node  
7) HIV encephalopathy 
8) Herpes simplex, chronic (>1 month), or bronchitis, 
pneumonia, or esophagitis.  
9) Histoplasmosis, disseminated or extra pulmonary 
10) Isosporiasis - intestinal (>1 month) 
11) Kaposi sarcoma 
12) Lymphoma (Burkitt‟s primary CNS)  
13) MAC disseminated or extra pulmonary 
14) M. tuberculosis - any site 
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15) Pneumocystis carinii pneumonia 
16) Pneumonia- recurrent 
17) Progressive multifocal leukoencephalopathy 
18) Salmonella septicaemiae, recurrent 
19) Toxoplasmosis- brain 
20) Wasting syndrome - HIV 
21) Any HIV infected individual with CD+ T cell count <200/µl 
has AIDS by definition, irrespective of the presence of 
symptoms or opportunistic disease”.  
WHO CLINICAL STAGING  OF  HIV/AIDS FOR ADULTS 
AND ADOLESCENTS 
Developed   by WHO  in 1990  and revised  in 2007.  
Based on clinical findings, that guides  diagnosis , evaluation, 
and  management   and  does not  require  CD4 count. 
Used   in   many  countries     to  determine   eligibility  for  
antiretro  viral  therapy.  
Categorized   as  1  to    4   stages  ,  progressing  from  
primary  HIV  infection  to  advanced  HIV/AIDS.  
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PRIMARY HIV INFECTION 
Asymptomatic  
Acute retroviral syndrome 
CLINICAL  STAGE I 
Asymtomatic 
Persistent   generalized   lymadenopathy 
CLINICAL   STAGE 2 
Moderate   unexplained  weight  loss [< 10%  of  presumed or  
measured  body  weight] 
Recurrent   respiratory   tract  infection 
Herpes   zoster 
Angular   cheilitis 
Recurrent  oral  ulceration 
Papular  pruritic  eruptions 
Seborrheic  dermatitis 
Fungal  nail  infection 
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CLINICAL   STAGE 3 
Unexplained  severe   weight  loss [> 10%  of  presumed  or  
measured  body  weight] 
Unexplained   chronic  diarrhea  for  more  than  one  month 
Unexplained  persistent   fever   >37.6*C  intermittent   or  
constant,  for  more  than  one  month 
Persistent   oral  candidiasis  
Oral  hairy  leukoplakia 
Pulmonary tuberculosis 
Acute  necrotizing  ulcerative  stomatitis  
Chronic  thrombocytopenia 
Unexplained anemia 
CLINICAL STAGE 4 
Pnemocysti  pneumonia 
HIV wasting  syndrome 
Recurrent   severe   bacterial   pneumonia  
Chronic   herpes  simplex   infection 
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Esophageal  candidiasis 
Extra pulmonary  tb 
Kaposi  sarcoma 
CMV  infection 
Cns  toxoplasmosis 
MAC  infection 
Disseminated mycosis 
Lymphomas 
Chronic  cryptosporidiosis  
HIV associated   nephropathy/cardiomyopathy.  
 
MODES OF TRANSMISSION AND DYNAMICS[9] 
Sexual Transmission 
 Sexual transmission- via hetero and homosexual contact.  
 Parenteral transmission:  among injection drug users (IDU), 
blood transfusions.   
 Perinatal transmission.   
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FACTORS  INFLUENCE THE SEXUAL TRANSMISSION 
Presence of other STDs 
 Strongly associated with HIV transmission 
 Genial infections  are linked to increased  risk of  hiv via     
sexual  transmission. e.g., Treponema pallidum, Haemophilus 
ducreyi and  herpes simplex virus. 
 The  non ulcerative  inflammatory genital infections like  
C.trachomatis,  N.gonorrhoea,   T.vaginalis also  increase  the  
risk  of  transmission. 
Level of Plasma Viremia:  
 The  main  factor  that  determines  the  heterosexual 
transmission is level of   plasma viremia. 
 Transmission is  rare  when  viral  load in  plasma less than 
1700 copies  of HIV RNA  per ml. Level of HIV RNA was 
highest at early phase of infection .   
Male Circumcision 
 It has lower risk of HIV infection.  
 In uncircumcised men  there is  increased  susceptibility of  
ulcerative   STDs,  and  a high  density  of  langerghans CD4  
cells  in  highly  vascularised   inner  foreskin. 
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Alcohol and illicit drug use 
 Its usage  increases the risk  of  HIV  transmission  via  
unsafe sexual behaviors, both homosexual and heterosexual.  
TRANSMISSION BY BLOOD AND BLOOD PRODUCTS [10, 11] 
Blood Product. 
The blood products that Capable of transmitting HIV 
transmission are 
 Whole blood, packed RBC‟s, Platelets  
 Leukocytes, plasma concentrates of clotting vaccine  
Not associated with HIV. 
While  processing  these  products  the  viral  elements are  
inactivated  or  removed. 
 Hyperimmune gamma globulin 
 HB immune globulin, plasma derived 
 Plasma derived hep B 
 Rho immune globulin.       
There  is  no  reported   case  of   HIV- 2   transmission  via  
donated  blood or  tissues  in  united  states.  
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TRANSMISSION IN  I .V. DRUG USER 
10,11
 
Occupational transmission: 
Transmission   through  intact  skin  has  not  been  
documented.  
Transmission to health care worker and laboratory from a 
health care personal who work with HIV-containing few materials.  
Transmission of infection worker to patients.  
Potential place of health care workers to get HIV infection 
Sl. 
No. 
Exposure Risk 
1. Needle stick injuries cut by sharp object  0.3% 
2. Contact with blood, tissue or other body fluid  0.09% 
3. 
Contact of non intact skin is less risk than mucous 
membrane                                                            
Factors associated with increased risk for HIV infection  
 Percutaneous exposure – high risk 
 Blood level: 
 Device visibly contaminated with patients blood  
 Needle placed directly in a vein or artery  
 Deep injury 
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Mucocutaneous exposure: 
 Exposure of  high volume  blood 
 Prolonged period of contact 
 Portal entry 
Exposure to  blood of advanced stage disease patients  
 High level titre of HIV in blood 
 More virulent strains of virus 
HIV containing material – different body fluids have different 
potential for HIV transmission.   they can be classified as:  
Highest 
risk 
Fluids considered potentially 
infectious (but risk much 
lower than blood exposure and 
not commonly implicated in 
occupational exposure) 
Fluid not 
considered 
potentially 
infectious unless 
visibly bloody 
Blood and 
visible 
bloody 
body fluids 
CSF, synovial-fluid, pleural 
fluid, peritoneal fluid, 
pericardial fluid, amniotic fluid 
Feces, nasal 
secretions, saliva 
sputum, sweat, 
tears, urine, 
vomitus 
FETAL / INFANT TRANSMISSION 
HIV transmission from an infected mother to her fetus can 
occur at various stage  
During pregnancy Perinatal period Breast feeding 
23 – 30% of cases 
Most common period  
(50 – 60%) 
2 – 20% 
Can occur as early as 1st and 2nd trimester  
 27 
Overall, probability of transmission (HIVfrom mother to fetus 
(in absence of prophylactic ART) is 15 – 25% in industrialized 
countries and 25 – 35% in developing countries.    
Factors associated with higher rates of transmission  
High maternal levels of plasma  viremia 
The risk increases steadily as the level of maternal plasma 
viremia increases. 
There is no cutoff value below that transmission never occurs.   
Low maternal CD4+ T cell count  
It is correlated with high levels of plasma viremia.  
Closer HLA – match between mother and child. 
 Factor important for transmission during labour or 
perinatal period is Prolonged interval between membrane 
rupture and delivery. 
 Factors associated with increased mother to child 
transmission via breast feeding.   
 Mastitis 
 Low level of  maternal CD4+ T cell counts 
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 Low level of vitamin A .  
 Breast feeding during early month 
 Mixed feeding – higher risk than exclusive breast feeding.  
GUIDELINES FOR DECREASING MATERNAL-FETAL 
TRANSMISSION 
Use of ART 
For mother who requires 
therapy for her HIV infection 
For mother who does not 
need treatment to HIV 
infection 
Combined treatment for mother 
during pregnancy through 
delivery + Prophylaxis for infant  
Antiretroviral prophylaxis with 
one or more drugs + 
Prophylaxis for infant 
In developing countries, if about regimens cannot be used, 
short course prophylactic ARV regimens can be used.  
OBSTETRIC MANAGEMENT 
 Combination ARV combined with cesarean section delivery, 
significantly decreases risk of maternal – fetal transmission. 
 Breast Feeding 
 In developed countries – avoidance of breast feeding by 
infected mother.  
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 Developing countries, the optimal approach is to provide 
continual treatment to infected mother who breast feed 
their infant.   Also, intermittent administrative of 
nevirapine to the uninfected babies is being tried.   
Mode 
Risk of 
transmission 
Number of 
cases 
Sexual route 0.01 – 1.0% >80% 
Mother to child route 30 1% 
Blood products 90 3 – 5% 
Infected syringes and needles 
– IDU 
0.5 – 1.0 – 10% 
WINDOW PERIOD  
Antibody detection                - 22 days 
P24 Ag detection          - 16 days  
Nucleic acid testing  - 12 days 
ELISA – STANDARD BLOOD SCREENING TEST FOR HIV 
INFECTION 
 Usually detects both HIV – 1 and HIV – 2 
 Sensitivity >99.5%; Specificity – not optional 
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 From positive Elisa to a negative Elisa on treatment does not 
indicate clearing of infection; it signifies levels of ongoing 
exposures to virus insufficient to maintain a measurable 
antibody response.     
WESTERN BLOT – (HIGHLY SPECIFIC) 
 Positive western blot – FDA criteria (1993) – Antibodies to 2 
of the 3 HIV proteins; p24, gp41 and gp 120/160.  
 Antibody band to polgene product p31 should also be checked 
to rule out false positive.  
 Negative western bolt – is one in which no bands are present 
at molecular weights corresponding to HIV gene products. 
 Causes – early HIV-1, HIV-2, pregnancy, antibodies that 
cross react with proteins of HIV ego antibodies that react 
with p24 and/or p55. 
For indeterminate cases: 
 Repeat western blot after 1 month 
 Attempt to confirm a diagnosis of HIV with: 
o P24 antigen capture assay 
o One of the tests for HIV RNA 
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P24 ANTIGEN CAPTURE ASSAY 
 Elisa or EIA – type assay 
 Positive in maximum up to 50% patients. 
 Greatest use – screening test for HIV infection during 
suspected acute HIV syndrome. 
HIV – RNA TESTING 
Very useful in settings where anti – HIV antibodies may be 
misleading. 
1. Acute infection 
2. Neonatal infection 
Methods Principle Sensitivity 
RT – 
PCR 
Target 
amplification 
Reliable to 40 copies/ml of 
HIVRNA 
B DNA 
Signal 
amplification 
Reliable to 50 copies/ml of 
HIVRNA 
LAB MONITORING OF PATIENTS WITH HIV INFECTION 
CD4+ T cell counts 
 Correct measure of immunologic competence to HIV infected 
patients. 
 Measurement made either 
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o Directly  
o Percent of CD4+ T cells and total lymphocyte count.  
 To Test the infection- during the time of diagnosis  and  evry 
3 -6 months. 
 Practical use of CD4+ T cell count: 
o If CD4+ Tee count <350/ml – indication for initiating ART 
therapy. 
o Decline in CD4+ T cell count >25% - indication of change 
the therapy. 
 CD4+  count is <200/ml – start regimen for p.jiroveci  
prophylaxis  
 If count <50/ml – start primary prophylaxis for MAC  
HIV RNA DETERMINATIONS 
 To Measure the change in HIV RNA levels useful  for  
o Assessing rate of disease progression 
o viral turnover 
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o Correlation between immune system activation and viral 
replication. 
o To assess the  occurrence of drug resistance  
 Decisions based upon HIV RNA level should never be made 
on a single determination, because of fluctuation during the 
secondary infections or immunization.  
 To measure HIV RNA levels during at the time of diagnosis 
and every 3 – 6 months for whom are all not taking ART.   
TEST OF HIV RESISTANCE 
 Done through – genotypic assays and phenotypic assays  
 They enhance short term ability to decrease viral load by 0.5 
log compared simply on changing drugs .  
 Useful for: to Select the new drugs,and initial regimen 
CO-RECEPTOR TROPISM ASSAYS 
 Important when treatment with CCR5 antagonist is planned  
 Usually done using a phenotypic assay  
Even though HIV causes immune suppression, it causes 
hypergammaglobulinemia rather than hypogammaglobulinemia.   
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 Increased p24 antibody; basis for detection in window period  
 T cell energy is commonly seen in HIV 
 Abnormal response of T cells to mitogens is a test used in HIV.     
DISEASE PROGRESSION11  
After  acute infection, HIV starts to destroy HIV-directed 
CD4+ cells; this  process destructs  the critical interaction between 
host CD4+ cells and CD8+ T cells  and  loosen  the  host  CTL 
response.  HIV highly seeds lymphoid organs and the central 
nervous system, the infection persists, and continued rounds of 
replication lead to the gradual depletion of CD4+ cell. Then 
activated, HIV-infected CD4+ cells returns to a dormant state 
remains latently infected.  The CD4+ T cell count provides an 
correct way to assess the current immunologic status.   HIV RNA 
level is strong predictor of the progression to AIDS in untreated 
HIV-infected persons.     
CLINICAL MANIFESTATIONS  
Acute HIV syndrome
12,13,14 
 Occurs in 50 – 70%  
 Typical viral illness : fever, malaise, myalgia, arthralgias, 
LAP, etc., 
 It Occurs 3 – 6 wks after HIV infection 
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 Completely resolved in 2 – 4 wks 
 High plasma viremia 
 High levels of p24 antigenemia 
o HIVRNA by PCR is used for diagnosis in this stage  
o Seroconversion, i.e., antibody positive by 3 – 7 weeks 
after infection 
o Dendritic lineage cells are first to be infected 
o Dissemination of virus occur o lymphoid organs where 
infection persists. 
o CD8+ cytotoxic T lymphocytes are responsible for 
containment of primary infection.  
o Initially, low CD4+ and low CD8+ counts; later in acute 
stage (and also in advanced HIV); low CD4+ and high 
CD8+ - inversion of CD4/CD8 ratio.  
 HIV escapes elimination from the body because of:  
 Deletion of CD8+  T cells due to overwhelming viremia  
 Sequestration of virus in lymphoid organs (cf CD8+ in 
peripheral blood) – NOT BECAUSE OF “MUTATION”. 
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o Possible neurological complications : meningitis, 
encephalitis, peripheral neuropathy, myelopathy 
CLINICALLY LATENT PHASE 
 Median time for untreated patients is 7 – 10 years 
 Telescoped to 3 yrs in rapid progressors  
 CD4+ counts decreases at the rate of 50 / mm3 per year  
 Virus replicates in LNs (whether or not LAP+) 
 One replication cycle = 1.5 days 
 1010 to 1011 virions produced per day 
 11/2 of infected CD4+ T cells is one day 
 11/2 of circulating virion is 30 minutes  
When CD4 count is in normal range (500 – 1600 cells/cmm or 
28 – 50%), the immune system defends itself against most antigens.    
SYMPTOMATIC DISEASE
14 
200 – 500 CD4+ count 
 Pneumococcal pneumonia 
 Pulmonary tuberculosis 
 Kaposi‟s sarcoma  
 Herpes zoster 
 37 
 Oral thrush 
 Cryptosporidum 
 Oral hairy leukoplakia 
<200 CD4+ count 
 Pneumocystis carinii pneumonia 
 Candida esophagitis 
 Recurrent/disseminated viral herpes simplex 
 Toxoplasmosis 
 Histoplasmosis 
 Coccidioidomycosis 
 PMLE 
 Extra pulmonary tuberculosis  
<50 CCD4 count 
 CMV 
 MAC 
 Primary CNS lymphoma 
RESPIRATORY SYSTEM [15] 
 The most  common  manifestation is pneumonia  
 The  most common  Opportunistic infection in HIV patients  
is Tuberculosis 
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 MC cause of pneumonia in HIV patient: Pneumococcal 
Pneumocystis jiroveci
16,17 
 Usually occurs in patients with CD4+ <200 
 Transmission is airborne 
 Pathology : binds to and damages type I pneumocytes; remains 
extracellular….and  there  is  hypertrophy of type II pneumocytes. 
 Presents with fever, nonproductive cough, retrosternal 
burning, pleuritic pain, dyspnea 
 Tachypnea, tachycardia, cyanosis  
 Chest exam : no findings / bibasilar rales 
 CXR : Normal in early disease and  bilateral  faint  interstitial  
infiltrate  later. And  there is  no  lymph  node  enlargement 
and  pleural  effusion.   
 „Classic‟ finding of dense perihilar infiltrate is unusual 
 Patients on AEROSOLIZED PENTAMIDINE  for prophylaxis can  
manifest  with Upper lobe cavities, pneumothorax, 
extrapulmonary  commonly lymphnode. 
 Hypoxemia, ↑LDH  
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DIAGNOSIS 
Demonstration of trophozolte / cyst is must  
 Silver Methenamine stain, Wright Geimsa-stain 
Sputum induction 
Brancho-alveolar lavage 
Trans-bronchial lung biopsy 
 Treatment of choice: TMP / SMZ (dose: 15-20/75-100 
mg/kg/d) for 21 days. 
 S/E: rash, BM suppression, hepatitis, hyperkalemia quite 
common in HIV patients.   
 If pO2 <70mmHg OR (A-a) O2>35mmHg:  ADD CORTICO 
STEROID.  
 Treatment in patient sensitive to sulfonamides: Pentamidine  
 Prophylaxis: 1 DS tablet of Cotrimoxazole daily.  
INDICATIONS 
All patients with prior PCP 
CD4+ count less than 200/cumm 
Pyrexia  of  unknown  orgin 
Oro-pharyngeal candidiasis 
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(This also provides prophylaxis against Toxoplasmosis, 
nocardiosis and bacterial infection.   
Alternative drugs for prophylaxis: Pentamidine/ Dapsone/ 
Pyrimethamine/ Atovaquone 
TUBERCULOSIS 
The number of HIV positives in India around 3.97 million 
cases. In AIDS affected cases, sixty percentage of patients had TB.   
HIV AND TB    
Early Disease (High CD4 count) 
Pulmonary disease more common 
Upper lobe 
Cavitation + 
Mediastinal  Lymph Nodes - 
Sputum positivity rate-higher 
Constitutional symptom – common (incl. cough and hemoptysis) 
Late Disease(Low CD4 count) 
Extrapulmonary disease commoner than pulmonary 
Lower lobe 
Cavitation  
Mediastinal  lympadenopathy 
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Sputum usually negative 
Uncommon 
Treatment of Tuberculosis in HIV affected patients  
 Anti-Tuberculosis treatment is the same for both HIV 
infected and  negative TB patients, except of the using the 
thiocetazone.  Thiacetazone having severe cutaneous 
reactions like Exfoliative Dermatitis , Steven Johnson 
syndrome  and  it can be fatal.   
 In place of TZN, use EMB in HIV+ve persons.  
 NRTIs can be safely co-administered with ATT. 
WHO recommendations 
 It recommends that people with TB/HIV complete their 
Tuberculosis treatment  prior to start  ART  unless there is a 
high chance of HIV disease progression and death during the 
period of tuberculosis treatment (i.e. a CD4 count <200/mm3 
or disseminated TB). 
 Where a person needs Tuberculosis therapy and ART 
concurrently, first line treatment include ZDV/3TC 
(lamivudine) or d4Tn (Stavudine)/3TC plus either an NNRTI 
or ABC (Abacavir).   
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 If patient need NNRTI-based therapy, EFZ (Efavirenz) would 
be the preferred drug as it aggravates the hepatotoxicity of 
TB treatment appears less compared to  Nevirapine.  
 HIV affected patients are not recommended during 
Tuberculosis therapy with rifampicin, except ritonavir.  
MAC
 
 Mycobacterium avium  intercellulare complex usually occurs 
in patients with CD4+ <50 
 M. avium commoner than M. intracellulare 
 Prior infection with M. tuberculosis decreases risk of MAC  
 Most commonly presents with fever, weight loss, night 
sweats: sometimes abdominal pain, diarrhea, LAP 
 Chest x ray shows  bilateral lower lobe miliary shadows  
Diagnosis : culture of blood / involved tissue e.g. sputum 
 Treatment : Clarithromycin + Ethambutol + Rifabutin (or 
rifampicin) / amikacin / ciprofloxacin 
 This treatment is continued till the time patient achieves 
CD4+ count more than 100/mm3 for more than 6 months.   
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 Primary Prophylaxis is given to patients with CD4+ count 
<50/mm3 in the form of Tablet Azithromycin 1200 mg once a 
week. 
 Rhodococcus, Cryptococcus, coccidiodomycosis can cause 
lung  parenchymal disease with  cavitation.   
NEUROLOGIC SYSTEM
18 
Opportunistic cns  infections: 
 Toxoplasmosis 
 Cryptococosis 
 CMV 
 HTLV-1 
 PML  by JC virus 
 Amebiasis 
NEOPLASMS 
 Primary CNS Lymphoma. 
 Kaposi s sarcoma 
MYELOPATHY 
 Vacuolar  myelopathy 
 Pure sensory ataxia 
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PERIPHERAL NEUROPATHY 
 Acute   and   chronic  inflammatory   demyelinating  poly 
neuropathy. 
 Mononeuritis   multiplex.  
 Distal   symmetric  poly neuropathy.  
ASEPTIC  MENINGITIS AND  MYOPATHY 
  
AIDS DEMENTIA COMPLEX
19 
 Also known as HIV encephalopathy.  
 Occurs in  late  stage  of  hiv  infection  and    sub -cortical  
dementia.. 
 Manifestations  are Lack of concentration, forgetfulness, 
difficulty performing complex tasks, ataxia, tremor.  
 In contrast to Alzheimer‟s disease (cortical dementia) 
aphasia, apraxia, agnosia are rare. 
 Bladder bowel involvement occurs in late  stages.  
 The  level  of Alertness  is  normal. (no detrioration in level 
of consciousness). 
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 Severity of cognitive dysfunction increases with declining 
immune function. And  low CD4 count.  
 Most common cause of seizures in HIV, 24 to  47%  of  first  
seizure due  t HIV  encephalopathy. 
 Improvement in cognitive function occurs with ART.  
Causes of seizure in HIV patient
19 
 Toxoplasmosis 
 Tuberculosis 
 PML 
 Cryptococcal meningitis 
 Metabolic and electrolyte disturbances  
 Drugs  
ORAL 
Infections 
Fungal 
 Candidiasis 
 Systemic fungal infection with oral lesion 
 Histoplasmosis 
 Cryptococcosis 
 Aspergillosis 
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Viral 
 Oral hairy leukoplakia EB virus 
 Herpes simplex CMV 
 Varicella zoster 
 Papilloma virus  
Bacterial 
 Periodontal infection 
Neoplasm     
Carcinoma 
 Squamosus cell Ca 
 Basal Cell Ca 
 Sarcoma 
 Kaposi sarcoma 
Lymphoma 
 NHL 
 Idiopathic oral aphthous ulcers  
 HIV salivary gland disease.  
Gastrointestinal manifestations[20] 
 Esophageal disease 
 Esophagitis – Candida, CMV, HSV 
 Gastric disease 
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 Gastric lymphoma 
 Atypical presentation of secondary infections  
 Leutic gastritis 
 Gastric TB 
 Intestinal manifestations 
 Diarrhoea 
BACTERIAL INFECTION 
Salmonella 
Shigella 
Campylobacter 
Clostritium  difficle 
PARASITIC INFECTIONS  
Small intestine 
Cryptosporidium 
Isospora 
Microsporidia 
Giardia 
LARGE INTESTINE  
Entamoeba histolytica 
Mycobacterial  
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 MAC 
 M.Tuberculosis 
Viral 
 CMV – Colitis 
 Herpes simplex 
RECTAL LESIONS  
Infections 
Perirectal ulcers 
HSV 
Condylomata acuminata 
Neoplasm 
KS 
IMPORTANT GIT MANIFESTATIONS
 
Esophagitis
 20
 
 Candida – is  the most common infection  and  AIDS defining illness 
and  oral candidiasis is associated with dysphagia  , odynophagia. 
 Definite diagnosis is possible on endoscopic biopsy.  
 CMV- single  large  ulcer   
 HSV- multiple  small ulcer 
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Diarrhea 
 The most common protozoan causing diarrhea : 
Cryptosporidium 
 Other causes  are   microsporidia, isospora belli, c.jejuni,  
shigella,  salmonella.  
HIV ENTEROPATHY / AID ENTEROPATHY 
 Diarrhea for >1 month 
 No  identifiable  cause of diarrhea  despite extensive 
evaluation  even   after upper and  lower  GI endoscopy..  
 Low grade Mucosal atrophy indicates hyporegenerative state 
and  diminished  or  absent  small intestinal  lactase  leads  to 
lactase deficiency causes malabsorption and weight loss.  
    HEPATOBILIARY DISEASES[20] 
 High incidence of HBV & HCV in HIV because of similar 
routes of transmission. 
 95% of HIV infected patients have evidence of prior/active 
HBV infection, of which 10% are HBsAg+ve 5 – 40% have 
HCV co-infection.   
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HBV CO-INFECTIONS
21  
 Increased in chronic HBV infection (HBsAg positivity after 
acute infection) 
 Decreased in inflammatory liver disease (lower ALT, milder 
histology) 
 BUT higher viral replication of HBV.  There is 10 folds 
increased  mortality in patients with active  infection.  
 Lamivudine , emtricitabine, adefovir, tenofovir and  entecavir 
, telbivudine   alone   or  in  combination  are useful  in 
treatment of  hepatitis  B in  patients with  HIV infection.  
HCV CO-INFECTION 
 More severe hepatitis and worse prognosis than with HCV alone 
 Increased   incidence of liver failure  
 Lack of sensitivity of serological tests (anti-HCV) in 
diagnosing HCV infection.  
 perinatal  and heterosexual transmission.  
 Treatment is pegylated interferon α with ribavirin  
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 CO-INFECTION OF HEPATITIS B OR C
 
 The possibility of additive hepatotoxicity regimens with 
dd1/d4T and/or NVP would be avoided in patients having  
active hepatitis. 
 3TC and TDF are highly active against hep B and new 
infection 
TREATMENT HIV INFECTION INCLUDES 
 Anti retroviral therapy  and  management  of  opportunistic  
infections.  
 Prophylactic interventions 
Table – Indications for the initiation of ART 22,23,24 
Acute infection syndrome 
Chronic infection 
a. Symptomatic state (including HIV-associated nephropathy) 
b. Asymptomatic state 
    1.  CD4+  count <500/L 
    2.  Pregnancy 
Postexposure prophylaxis 
Antiretroviral therapy 
Combination ART therapy or highly active antiretroviral 
therapy (HAART) is the major role in management of patients with 
HIV infection. 
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TO CHANGE THE REGIMEN-THE FOLLOWING 
PRINCIPLES    ARE UESD 
 Single  drug  would  not be added or changed to a falling 
regimen; only if resistance   testing  has been done and it 
shows resistance to one drug, then to change one drug only.  
 Cross-resistance among NNRTIs is common and therefore 
changing between NNRTIs should be avoided in PI therapy; 
nelfinavir should always be given first.  
 Cross resistance in common between ritonavir and indinavir 
and changing between these 2 drugs should be avoided.   
Immune Reconstitution Syndrome 
 TB  is  the common opportunistic  infection.  
 For patients with TB, this syndrome occurs in about 30% of 
patients.   
 The syndrome is manifested by fever, lymphadenopathy, 
pulmonary lesions (by X-ray) and expanding   central   
nervous  systems lesions.   
 Typically self-limited one, to start the use of a short course of 
corticosteroids.   
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 ART would not be stopped for immune reconstitution 
syndromes and antimicrobial therapy for the OI should be 
started with ART. 
Post Exposure Prophylaxis (PEP) 
 The rationale   in PEP is that systemic infection does not 
occur immediately after an exposure, leaving a brief window 
of opportunity during which post exposure antiretroviral 
intervention may modify or prevent viral replication.  
 PEP   should   be   initiated    preferably   within 1 to 2 hours post 
exposure and up to 36 hours.  PEP   should   be   discouraged 72 
hours after exposure.  It should be administered for 28 days. 
ARV REGIMEN 
Basic Regimen :  Zidovudine    300 mg  BD   +  Lamivudine         
150 mg BD for 28 days  (Or)  Stavudine 30/40 mg  BD  + 
Lamivudine 150 mg BD 
Expanded  Regimen :   Above regime + Indinavir 800 mg tds 
for 28 days (Or)  Above regimen + Efavirenz 600 mg HS for 
28 days.   
The health care worker should be tested for HIV as per the 
following schedule: 
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 Baseline HIV: At the time of exposure 
 Repeat HIV: At 6 th week,   12 th week  and  6 month   
following  exposure.  
 Pre and post test counseling should  be needed.  
During this period, HCW should not: 
Donate blood / semen / organs 
Indulge in unprotected sex 
Breast feed her infant 
Become pregnant 
New Drugs  
Ritonavir 
Indinavir 
Nelfinavir 
Atazanavir 
Tipranavir 
Darunavir 
Maraviroc 
Entry inhibitors 
Enfuvirtide 
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Changing   the  ART  regimen if 
 Less than a one-log drop in plasma HIV RNA by four weeks 
following ART. 
 A reproducible significant increase from the nadir of plasma 
HIV RNA level not attributable to intercurrent infection, 
vaccination or test methodology.  
 Persistently declining CD4+ T cell numbers 
 The adverse   effects   of   the  ART. 
 Patients   clinical   detoriation.  
NEW DRUGS : RECENT ADVANCES 
Entry Inhibitors: 
Maroviroc 
Enfuvirtide 
Acts by inhibiting virus entry via CCR5 coreceptors  
It doesn‟t inhibit virus taking entry with the help of CXCR4 
Very potent drug and resistance is difficult to develop  
Side effectS. 
 Hepatotoxicity 
         Hypotension   due  to alpha  blockade.  
Rash 
Hypersensitivity 
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VIRAL  INTEGRASE  INHIBITOR 
Raltegravir 
Elvitegravir 
 Used in resistant HIV infection 
 Used in combination as a part of HAART 
 Does not cause lipodystropy.   
 57 
HIV ENDOCRINOPATHY 
The  every  endocrine  organ  can  affected  by  HIV, may  
leads  to  functional  derangement  of  that  endocrine  gland. A   
pandemicity   of  HIV  and  survival  benefit  of  HAART  makes  
high  incidence  of  endocrinopathies    in  last  two  decades.  
HIV   Endocrinopathy  - currently   a new  emerging   field  
of  modern  Medicine. 
HIV   Endocrinopathy  grouped  into 
25-27
 
 Primary  
 Secondary . 
Primary  
Related   to  direct  effect of  human  immunodeficiency virus itself. 
Secondary  
Related  to  indirect  effect  of   HIV  mediated   by 
1) Cytokine 
2) Immune   reconstitution. 
3) Opportunistic infections 
4) HAART 
5) Rarely neoplasms. 
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The   Endocrine   abnormalities   seen  in   early  and  late  
stages  of HIV  infection.  
The Commonly involved endocrine organs are  
1) Adrenal Gland  
2) Gonads 
3) Thyroid gland 
4) Pituitary and hypothalamus 
5) pancreas 
The  involvement   of  endocrine   organ  leads  in  poor  
quality  of   life and  significant  mortality   and  morbidity.  
 There   is  more  complex   interaction  between  HIV  and  
Endocrine  organs  which  can  leads to variable [mild  to  
severe] changes  in  hormone  secretion , transport , 
metabolism. Rarely   hormone   resistance   and   organ  
failure   seen  in  HIV patients. 
PATHOPHYSIOLOGY OF HIV ENDOCRINOPATHY 
1.The   progressive    immune      dysfunction  caused  by   
HIV   alters the   internal    environment    by   activation  of   
cytokines,  chemokines, antibody  formation,   and   by   immune   
reconstitution .  
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The   relation  between  HIV  and   Endocrine  function , 
secretion   mainly  centers   on  immune modulatory    effect  of  
cytokines   at  every  level   of   endocrinal   axis [ Hypothalamo –
Pitutary –Effector organ ] 
The  adrenal  gland  a  main  target  organ   in   HIV   and  
adrenalitis  is well known entity..
28-30 
HIV   Infection   triggers   the   activation   of     macrophage  
to secretes interleukins -1 , and  tumor necrosis  factor   a potent    
adrenal   stimulator.
31-32
 
HIV  infection    may  cause  polyclonal  B cell  activation  
and production  of   antibodies   against  glandular  cells  , there by  
inhibiting  glandular   endocrine  function.
33
  
2. Structural   Destruction  Of    Endocrine  Tissue:  
In  HIV  every  endocrine   organ   can   secondarily   affected  by 
 Opportunistic infections  
 Hamorrhage  
 Neoplastic process 
 Other  nonspecific  inflammation.  
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 Adrenal   destruction   mostly  caused    by   CMV  in  40 to 
90%  of  HIV Adrenalitis.
34
 Other causes  are -   
mycobacterium   tuberculosis,   MAC,  Cryptococcus, and  
hemorrhage. 
 Pnemocysti thyroiditis  cause  painful  thyroiditis  may  leads  
to  hyper   followed  by  hypothyroidism.
35
 
 Pitutary    and   Hypothalamus   destruction   can   also   
caused  by  Toxoplasmosis,  Cryptococosis  , CMV infection.  
3. Endocrine Effects of Medications 
Medications    used   in   HIV   can    cause    endocrine   
dysfunction commonly, they   primarily   contributes   to   the  
alterations  in  
1) Lipid Metabolism 
2) Insulin Sensitivity 
3) Bone mineral Homeostasis. 
4) Fat Redistribution. 
5) Lipid Profile. 
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PROTEASE   INHIBITORS 
36-37
 
May have direct effects on Adipogenesis  via  
 Decreased nuclear  localization  regulatory   element  binding 
protein [SREBP-1].  
 Reduction  in  peroxisome  proliferator   activated   receptor  
gamma [PPAR gamma]. 
 Other relevant endocrine effects  are Fat Redistribution, 
Hypertriglyceridemia, and increased production of small   
dense  atherogenic   LDL 2   molecules.  
 PIs  can   cause   decreasing   GLUT4    activity    and  
Insulin   Sensitivity  resulting   in  Hyperglycemia.  
NUCLEOSIDE   REVERSE    TRANSCRIPTASE    
INHIBITORS 
38
 
 Like PIs, NRTI also causes fat redistribution, hyperglycemia,  
loss of appetite, Subcutaneous fat loss,  gynecomastia. 
 Can   also   cause   Renal  tubular  dysfunction..  
NUCLEOTIDE REVERSE TRANSCRIPTASE    INHIBITORS 
 Tenofovir Metabolised by plasma esterase, associated with  
fat   redistribution    and     hypophophatemia.  
 62 
NON- NUCLEOSIDE  REVERSE   TRANSCRIPTASE   
INHIBITORS 
39-40
 
These   drugs   metabolized    by   cytochrome    pathways,   
and are associated    with   hyper lipidemia  ,  fat   redistribution..  
Drugs   other than   anti   retro viral , in addition  antifungal , 
antibiotics, chemotherapeutic    agents  used    in   opportunistic   
infections   in HIV   patients   can   also   have  adverse effect on 
Endocrine function. 
Idiopathic    adrenohypophyseal   necrosis 
41
    observed     in   
10%  of HIV     patients    thought   to   be   direct  effect of hiv.  
Hyper prolactinemia    and   gynecomastia   reported   in   
more   than   20% of   HIV  patients  and   associated   with   
increased CD4  count, thought  to be  HIV   infection  reduces  the   
dopaminergic  tone  and   increases  the  bioactivity  of  
prolactin
42,43 
HYPOGONADISM
44-46 
Primary 
HIV   induced   immunomodulators   causes  
TNF   Mediated   inhibition of steroidogenesis by  altering the 
side  chain cleavage. 
 63 
IL-1 Prevents  leydig  cell  steroid  production  and  
leutinizing  hormone  binding  to  leydig cells. 
Secondary 
 Hypogonadism   in   HIV  patients   mostly  secondary .  
 Low  Gonadotropin  Level  due to  the effects  of ,47  
 Under   nutrition. 
 Infection - Inflammation. 
 Drugs effects on gonadotropin production..  
 
 Clinically,  male  patients   with    advanced   disease   have,  
Loss of libido   –   67% 
Impotence        –   33% 
 Ovarian    Dysfunction   in   female   is   less  common,  can  
cause  Amenorrhoea  around   25%    patients   during   stress  
of illness,   Anovulation    seen   in   half   of  patients   with   
low   CD4   count
48,49
 
 Early   Menopause   up to  8%  of  HIV  infected   female   
patients.  
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PANCREATIC DYSFUNCTION
50,51 
 A   target   organ  of  opportunistic  infection,  and  
malignancies [ lymphoma, Kaposi sarcoma].  
 Pancreatitis   and   hypoglycemia   are   major   clinical 
manifestations.. 
 Pancreatitis   commonly   caused   by  drugs  Didanosine , 
Zalcitabine, Trimethoprim,    Pentamidine
52-54 
. 
 Hypoglcemia   results  from  islet  cell  inflammation and  
insulin  release.                             
HIV   AND   THYROID   DYSFUNCTION: 
Thyroid Gland: 
55
 
In   Greek   Thyreos   means - Shield,  Eidos  means - Form..                                
Thyroid   Gland  located   in  anterior  to   trachea,   and  
consists  of     two  lobes, connected  by  isthmus..  
 The  Normal  Size  of  Thyroid  gland  is  12  to  20  gram.  
 Throid   Gland   Develops   from   the  floor  of  primitive  
pharynx  during  3 rd   week  of   Gestation   and  its  
Migrates  along  Thyroglossal  duct  to  reach  Neck.. 
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Thyroid   Hormone   Synthesis   begins   at  11  week  of  
gestation. 
 Thyroid    Gland  produces  thyroxine [ T4],  and  Tri 
iodothyroxine  [T3] , and  these  Hormones   acts  through   recptor 
alpha  and  beta.. Regulation of   thyroid    gland   function   via   
HYPOTHALAMO – PITUTARY-THYROID   AXIS. 
 TSH  and  TRH   Secreted   from  hypothalamus  and  pitutary  
gland  respectively, control  over  thyroid  gland  function  in 
a  feedback  manner. 
 Thyroid   hormones   plays  critical  role in  CELL  
DIFFERENTIATION  during   development ,  and   maintain  
Metabolic  ,  Thermogenic  HOMEOSTASIS. 
THYROID   FUNCTION   ABNORMALITIES 
 Hypo thyroidism :  low  free T3 , T4  and   increased TSH.  
 Subclinical   hypothyroidism :  Normal Free T3, T4, and  
increased  TSH. 
 Hyperthyroidism :  Increased  Free T3 , T4  and  undetectable  
or low level TSH. 
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 Subclinical   hyper thyroidism : Normal  Free  T3, T4,  and   
Low  level of TSH. 
 Central   hypothyroidism :  Both  TSH  and   Free T3, T4  are  
decreased. 
CLINICAL FEATURES OF  THYROID DYSFUNCTION: 
Hypothyroidism 
Symptoms 
 Constipation 
 Weight gain  
 Hoarseness of voice 
 Cold intolerance 
 Dry skin 
Signs 
 Bradycardia 
 Delayed  tendon reflex 
 Carpal tunnel syndrome. 
 Serous  cavity  effusion. 
CLINICAL FEATURES OF  HYPERTHYROIDISM: 
Symptoms  
 Palpitation. 
 weight  loss. 
 Diarrhoea 
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 Irritability. 
 Heat intolerance. 
Signs 
 Tremors. 
 Lid lag. 
 Tachycardia, arrhythmias.  
 Proximal myopathy. 
 Gynecomastia. 
LABORATORY TESTS FOR THYROID FUNTION 
 Measures  TSH  and  Free or Unbound  T3, T4  levels.  
 Antibodies   to  thyro peroxidase  and  thyroglobulin..  
 Radioactive   iodine   uptake. 
 Ultrasonogram   neck.  
THYROID   DYSFUNCTION   IN   HIV 
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 Thyroid   function   alters   in   10  to 15%  of  HIV  patients.                     
 Most   asymptomatic  HIV  patients  with  stable  body  
weight  maintain normal  thyroid gland  function..
56-57
 
 Among  HIV  patients  1 – 2%   have  overt  hypothyroidism  
and  about  35%  patients  may  have  subtle  abnormality.  
58- 60
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The abnormalities  of  thyroid  gland  function  in  HIV 
patients  may  be  due to 
61-62
 
 Direct effect of HIV itself.  
 Opportunistic  infections infiltrates  or infect  thyroid 
gland.
63-65
  
 Cryptococcus neoformans. 
 Cytomegalo virus. 
 Visceral  leishmaniasis. 
 Suppurative   bacterial infection.  
 Mycobacterium tuberculosis. 
 MAC 
 Histoplasmosis 
 Neoplastic  infiltration 
 Kaposi sarcoma. 
 Lymphoma.  
 Occult papillary carcinoma. 
 Effects  of   Highly  active  antiretroviral  therapy.  
 Stress Of  Advanced  Disease.  
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The   Various  Thyroid  function  abnormalities  seen in HIV 
patients  these are, 
 Subclinical  Hypothyroidism. 
 Overt  Hypothyroidism. 
 Immune  Reconstitution  Graves Disease. 
 Isolated  Low  T4  Level.  
 Non thyroidal  Illness  or   Sick Euthyroid Syndrome.  
Beltran et al  studied  thyroid  function  abnormalities  in  350  
HIV patients  and  reported  that , increased   prevalence  of  
primary  hypothyroidism  in HIV  patients.
66-67 
Studies showed, 
Overt hypothyroidism             - 2.6% 
Subclinical hypothyroidism    - 6.6%  
Isolated  FT4 Level                 - 6.8%  
Among  350  HIV patients studied 
Beltran et al  and  Quirine et al  ,  collazos et al
68
  reported  
the prevalence  of  sub clinical Hypothyroidism  in both  ART  
naïve  as  well  as  in  patients  on  ART   were  similar..  
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In  Contrast,   Nelson  et al 
69
 and  calza  et al 
70
 reported  as   
high  prevalence  of subclinical  hypothyroidism  in  patients  on  
HAART.. 
Hepatitis   co infection  associated   with  Hypothyroidism    
mediated  by  autoimmune  process  or  by  adverse  effects  of  IFN  
alpha  therapy..
71-72
 
RISK FACTORS   FOR THYROID  DYSFUNCTION IN HIV
73-75
 
 Low  CD4  count. 
 Male   sex. 
 Longer   Duration   HIV  infection.  
 Older   Age. 
 Co Infection   with    Hepatitis  C  virus.  
 Patients   on   HAART. 
 Opportunistic   infections. 
 Immune   Reconstitution. 
INDICATION FOR THYROID TESTING IN HIV PATIENTS
76 
 Symptoms  of  Hypo  or  Hyperthyroidism.  
 Osteopenia. 
 Dyslipidemia 
 Depression. 
 Arrythmias  [Atrial fibrillation].  
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ISOLATED  LOW T4 LEVEL
77-81 
 Especially  patient on  HAART. 
 Reported  prevalence  1.3  to  6.8 %. 
 In HAART didanosine , stavudine  and  ritonavir  associated 
with this condition
82
 
SUBCLINICAL HYPOTHYROIDISM 
The   most  common    thyroid    abnormality  in HIV patients  
on HAART, with      elevated  TSH Level and  normal  T3, T4..  
The   Prevalence  of   Subclinical  Hypothyroidism  in
,83
 
General  population              -  4.3%.  
HIV patients  on  HAART   -  3.5  to  12.2%. 
Anti  thyro peroxidase   antibodies  seen  in,  
 50 to  80%  of    SCH   patients  in  general  population.84-85 
 Among   SCH   in   HIV   Patients , the  anti  TPO  abs  rarely 
identified.  And   suggest   the  etiology  may  not  be  
autoimmune itself.  
Beltran   reported   subclinical   hypothyroidism  in   HIV   
patients   associated with    Low   CD4  count  and   stavudine  
therapy. 
86
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OVERT HYPOTHYROIDISM 
The Prevalence overt hypothyroidism in various studies in 
HIV patients are, 
Beltran et al   -  2.6% 
Madge et al    -  2.5% 
Nelsons  reported ,  
The   expected    incidence   of    hypothyroidism  in  patients  
on   HAART,  and    recommends  Universal Screening  of  HIV 
patients  on  therapy. 
The  prevalence  of  hypothyroidism:
87,90
 
 In  general  population                          -  0.3% 
 In  HIV  infected  patients  varies         -  0  to  2.6%. 
May   be   associated   with   anti  TPO  antibodies.  
GRAVES DISEASE 
 Commenest     among    HIV   immune    reconstitution   syndrome,  
Prevalence
91
 
Woman       -   3%. 
Men           -  0.2%. 
 Autoimmune   mediated   production    of    anti  TSH  
receptor   antibodies. 
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 It  is  the  leading  cause  of  overt  hyperthyroidism  in  both  
general population   and  HIV patients. 
 
 In  HIV  patients  may  occurs  after  immune  restoration   by  
HAART    and  it is   most  commonly  diagnosed  at  12 – 36  
months  after  HARRT  initiation.
92 
 IFN   alpha   used  in  hepatitis C  infection  also associated  
with  graves disease. 
 Radioactive   iodine   uptake   study   shows   high  uptake  in  
graves disease  and  Low  uptake in  thyroiditis..  
MANAGEMENT OF THYROID DYSFUNTIONS IN HIV 
PATIENTS: 
Overt  Hypothyroidism.
93
 
 Treated  with  levothyroxine  and  maintain TSH  Level at 
0.5- 2.5 Mu\L. 
 Drug   interaction  between  protease  inhibitor  and  
levothyroxine  also reported   due  to  shared   glucuonidation   
pathway 
Subclinical  Hypothyroidism.
94,95
 
 In    HIV   Patients   with   sub clinical  hypothyroidism   , 
recheck  TSH Level  1 – 2 months  Later. 
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 In  general  population   TSH   Normalize   within  1 year  in  
about   30%  of   patients,, but  in  HIV  patients  the   
proportion   of  normalization level  may  be   Lower.  
 If  TSH  Level  persists   more  than 10  Mu\L    may  
considered treatment  with    levothyroxine.  
 Patients   may   treated   with  thyroxine   if   symptoms of 
hypothyroidism   or  pregnancy, dyslipidemia,  with  TSH  
level  between  5.5  to  10  Mu/L..  
Hyperthyroidism.
96
 
 Treatment    Depends  on  underlying  cause.  
 In  case  of   Graves  disease  treated   with   antithyroid   
drugs , and  definitive  treatment   with  radioiodine  ablation,  
or  surgery  may  be appropriate   in   some  patients. 
 Toxic   multi nodular   treated   with    radioiodine  ablation  
or  surgery. 
 Sub acute   thyroiditis   treated  with   NSAIDS  or  STEROIDS. 
 Regardless   of   cause   patients   with   hyperthyroidism   
treated with  beta   blocker  for  control  over   hyper 
adrenergic   symptoms. 
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 Various   studies  shows  that   TSH  negatively  correlate 
with  CD4 count  and   positively  with  HAART.  
Various   studies    shows   that    there    is   negative  
correlation  between   TSH   and    CD4    count…positive  
correlation  with  free  T3   and   free T4  and   HAART     therapy.  
Abnormal   thyroid   function  common among  in HIV 
patients  especially during  HAART. 
Currently  insufficient  evidence  in favor  of  screening  for  
thyroid  abnormalities  in  asymptomatic  HIV  patients  ,, and  need   
further Larger studies.
97
 
Thyroid   involvement  in  HIV   infection  confirmed  by  
various  studies  and  exact  mechanism   still   unknown.,  may   be  
related  to  direct  effect  of  virus,  opportunistic  infection,  
autoimmune , medication  to  treat   HIV. 
Thyroid   hormone  plays a  fundamental  role  in  metabolism  
and  immune  both  cellular  and   humoral   regulation, and  
recognition  of  these abnormalities   may  contributes  to  complete  
the  characterization  of  different  stages  the   HIV   infection  and   
their  treatment  and  may   be  important  for a  better  management  
of   hiv  patients.. 
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Larger   studies  are  needed   to  examine   the   
epidemiology   and  health  consequence   of   mild  thyroid  
function  abnormlities  in   HIV   patients  and  to  better  screen ing  
and  treatment  guidelines. 
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           MATERIALS   AND   METHODS 
This   case control   study   was   conducted  in  the  Rajiv  
Gandhi  Government  General  Hospital , Madras  Medical  College   
in  the   department  of   institute  of  internal  medicine  in 2014.    
The   total   number   of    patients  to  be  studied  in the  
study  was  100.   Patients   are  selected    from  people  a ttending  
OPD at   ART  CENTRE  madras  medical  college   and   Ethical  
Committee  clearance   was  obtained  for  this  study..  
STUDY CENTER  
Rajiv   Gandhi   Government   general  hospital, Madras 
Medical College. 
STUDY   DURATION  
6 Months – April 2014 to September 2014. 
STUDY   DESIGN  
Cross  Sectional  Observational  Study.  
INCLUSION CRITERIA  
1) Age  more  than  18  years 
2) HIV   patients    irrespective  of   stage  on  HAART.  
3) Sex  -   both  male  and  female  
4) Patient   willing    to   give  written   informed  consent. 
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EXCLUSION   CRITERIA: 
1) critically    ill  patients.  
2) Known   thyroid   disease   patients.  
3) Aged   less   than   18  years. 
CLINICAL   PROFILE 
The  following  parameters  assessed  in  HIV  patients  on  
HAART. 
1) Age  and   sex 
2) Stage   of   HIV infection. 
3) ART regimen 
4) Duration  of  therapy 
5) Symptoms  of  thyroid  dysfunction.  
 SYMPTOMS 
Regarding   hypothyroidism  - constipation,  weight  gain,    
cold intolerance,  fatigability,  menorrhagia, hoarseness   of  voice.  
Regarding   hyperthyroidism 
Irritability,  dysphoria,  diarrhea, polyuria,   oligomenorrhea,  
palpitations,  heat  intolerance.  
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PHYSICAL  EXAMINATION 
 Thyroid  examination. 
 Pulse  rate  and  blood  pressure. 
 Dry  skin 
 Tremors  
 Ocular  examination. 
LABORATORY  PARAMETERS 
Biochemical 
 THYROID  FUNCTION  TEST .   
 CD4 COUNT. 
  Thyroid functiontest. 
TSH -   using   ultra    sensitive   sandwich   chemi   
luminescent  immuno  assay.  
  FREE   T4  and   FREE T3 -   using   competitive  chemi  
luminescent  immuno assay.  
Patients   symptoms   and    thyroid  function   test    ,  CD4   
count   analyzed with   various  parameters.    
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Overt hypothyroidism 
 low   free  T3 and   T4    with  elevated  TSH.  
 Sub   clinical   hypothyroidism: 
 Normal   free   T3, T4   and   elevated   TSH   level.  
 Overt   hyperthyroidism: 
 Elevated   free   T3 , T4  and   very  low  or  undetectable  
TSH. 
 Sub   clinical   hyperthyroidism: 
 Normal   free   T3, T4   and   very low   or   undetectable   
TSH. 
The   symptoms   and   signs,  biochemical  parameters  were  
done   in  each    patient   and   analyzed  with  appropriate   
statistical  method.  
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OBSERVATION   AND   RESULTS 
FREQUENCY TABLE 
Table A: Age distribution of studied patients:  
 Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid 18-39 51 51.0 51.0 51.0 
40-59 48 48.0 48.0 99.0 
> 60 1 1.0 1.0 100.0 
Total 100 100.0 100.0  
0
10
20
30
40
50
60
18-19 40-59 More than 60
Age
 
Distribution of age among  studied  population.  
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Table B: Sex distribution of studied patients  
 Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid Male 61 61.0 61.0 61.0 
Female 39 39.0 39.0 100.0 
Total 100 100.0 100.0  
0
10
20
30
40
50
60
70
male Female
SEX
 
Distribution of  sex  among   100  studied  patients.  Males 
were 61 and Females were 39 in our study group.  
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Table C: Disease stage distribution of studied patients  
 Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid I 71 71.0 71.0 71.0 
II 18 18.0 18.0 89.0 
III 10 10.0 10.0 99.0 
IV 1 1.0 1.0 100.0 
Total 100 100.0 100.0  
0
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20
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40
50
60
70
80
Stage 1 Stage 2 Stage 3 Stage 4
WHO Stage
 
Distribution of HIV stage among  study  populatioN. 71%  
Patients Are In Stage 1 
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Table D: ART regimen distribution of studied patients 
 Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid ZLN 82 82.0 82.0 82.0 
ZLE 16 16.0 16.0 98.0 
TLN 2 2.0 2.0 100.0 
Total 100 100.0 100.0  
0
10
20
30
40
50
60
70
80
90
ZLN ZLE PLN
ART Regimen
 
Distribution  of  ART regimen in study population.  
Most of patients  are in ZLN regimen- 81% 
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Table E: ART   duration  distribution of studied patients  
 Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid < 2 30 30.0 30.0 30.0 
2-5 60 60.0 60.0 90.0 
> 5 10 10.0 10.0 100.0 
Total 100 100.0 100.0  
 
0
10
20
30
40
50
60
Less than 2 yr 2-5 yr more than 5 year
ART Duration 
ART Duration
 
Distribution of ART  duration among  study  population. In our 
study group most of the patients ART duration under 2 to 5 years.  
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Table F: Free TSH distribution of studied patients  
 Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid Normal 89 89.0 89.0 89.0 
Abnormal 11 11.0 11.0 100.0 
Total 100 100.0 100.0  
0
10
20
30
40
50
60
70
80
90
<.30 .30-5.5 >5.5
TSH
 
TSH Distribution Among Studied Population Shows the 
Prevalence of Thyroid Dysfunction Is 11% 
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DESCRIPTIVE STATISTICS 
Mean   and   standard   deviation   of   variables   study   group.  
 N Minimum Maximum Mean 
Std. 
Deviation 
Free T3 100 1.0 3.2 2.106 .3290 
Free T4 100 .6 1.5 1.012 .1896 
TSH 100 .36 150.00 4.8026 14.79200 
CD4 count 100 86 1619 501.46 262.302 
Valid N 
(listwise) 
100     
Mean  CD4  and  TSH  in our  study  population  is  501.46  
and  4.80  respectively…  
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 CORRELATIONS 
Correlation   between   free T3, T4 , TSH  with  CD4 count.  
  Free T3 
Free 
T4 
TSH 
CD4 
count 
Free T3 Pearson 
Correlation 
1 .231(*) 
-
.358(**) 
.169 
Sig. (2-tailed) . .021 .000 .094 
N 100 100 100 100 
Free T4 Pearson 
Correlation 
.231(*) 1 -.234(*) .120 
Sig. (2-tailed) .021 . .019 .236 
N 100 100 100 100 
TSH Pearson 
Correlation 
-
.358(**) 
-
.234(*) 
1 -.173 
Sig. (2-tailed) .000 .019 . .086 
N 100 100 100 100 
CD4 
count 
Pearson 
Correlation 
.169 .120 -.173 1 
Sig. (2-tailed) .094 .236 .086 . 
N 100 100 100 100 
 
This  table  shows  correlation  between   Free   T3, Free T4, 
TSH with CD4 count.  There  is  positive   coreelation  between   
free T3, T4,with CD4 count… and   negatively correlates with 
TSH.. 
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CROSS TABLES 
Table 1: Relationship   between   Free  T3  and  CD4. 
  
CD4 count 
Total 
< 200 
200-
350 
> 350 
 
Free T3 
Normal Count 8 21 67 96 
    
% within 
Free T3 
8.3% 21.9% 69.8% 100.0% 
    
% within 
CD4 
count 
72.7% 95.5% 100.0% 96.0% 
Abnormal Count 3 1 0 4 
    
% within 
Free T3 
75.0% 25.0% .0% 100.0% 
% within 
CD4 
count 
27.3% 4.5% .0% 4.0%  
Total Count 11 22 67 100 
% within 
Free T3 
11.0% 22.0% 67.0% 100.0% 
% within 
CD4 
count 
100.0% 100.0% 100.0% 100.0% 
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CHI-SQUARE TESTS 
 Value Df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 18.324(a) 2 .000 
Likelihood Ratio 12.562 2 .002 
Linear-by-Linear 
Association 
15.178 1 .000 
N of Valid Cases 100   
Table 1  shows  that  low  T3  patients  have   CD4 count  less 
than 200 and   pearson chi square   significant  Level is .000  and  
likely hood  ratio is  .002. 
RELATIONSHIP BETWEEN FREE T3 AND CD4 
Free T3
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CD4 count
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200-350
> 350
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.TABLE 2: RELATIONSHIP   BETWEEN   FREE T4  
AND  CD4 
 
  
CD4 count 
Total 
< 200 
200-
350 
> 350 
Free T4 
Normal Count 8 22 66 96 
    
% within 
Free T4 
8.3% 22.9% 68.8% 100.0% 
    
% within 
CD4 
count 
72.7% 100.0% 98.5% 96.0% 
Abnormal Count 3 0 1 4 
    
% within 
Free T4 
75.0% .0% 25.0% 100.0% 
% within 
CD4 
count 
27.3% .0% 1.5% 4.0%  
Total Count 11 22 67 100 
   
% within 
Free T4 
11.0% 22.0% 67.0% 100.0% 
   
% within 
CD4 
count 
100.0% 100.0% 100.0% 100.0% 
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CHI-SQUARE TESTS 
 Value Df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 17.529(a) 2 .000 
Likelihood Ratio 10.303 2 .006 
Linear-by-Linear 
Association 
9.938 1 .002 
N of Valid Cases 100   
Table  2  shows  there is  positive  correlation between  Free 
T4  and  CD4  count,  low  T4  level  patients   are  mostly   have   
low  CD4  count.   Pearson chi square .000  and  likely hood ratio   .006      
Relationship  between  Free T4  and   CD4 count.   
Free T4
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> 350
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Table 3: Relationship   between   TSH   and  CD4. 
  
CD4 count 
Total  
< 200 
200-
350 
> 350 
 
TSH Normal Count 3 21 65 89 
 
Abnormal 
    
% within 
TSH 
3.4% 23.6% 73.0% 100.0% 
    
% within 
CD4 
count 
27.3% 95.5% 97.0% 89.0% 
Count 8 1 2 11 
Count 
    
% within 
TSH 
72.7% 9.1% 18.2% 100.0% 
72.7% 4.5% 3.0% 11.0%  
% within 
CD4 
count 
11 22 67 100 
 
Total    
% within 
TSH 
11.0% 22.0% 67.0% 100.0% 
   
% within 
CD4 
count 
100.0% 100.0% 100.0% 100.0% 
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CHI-SQUARE TESTS 
 Value Df 
Asymp. Sig.  
(2-sided) 
Pearson Chi-Square 48.144(a) 2 .000 
Likelihood Ratio 30.290 2 .000 
Linear-by-Linear 
Association 
32.060 1 .000 
N of Valid Cases 100   
Table 3  shows  there is negative correlation between  TSH  
and  CD4  count.  Out  of  11   abnormal[>5.5]   TSH  patients  , 8  
are  have   CD4  count  <200. 
Pearson chi square  significant  at .ooo   and   liklyhood  ratio  is  .000 
TSH
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Correlation between TSH and CD4 count. 
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CORRELATION BETWEEN SEX  AND   TSH COUNT. 
Most  of  abnormal  TSH  level  patients  13%  are  MALE 
sex..indicates  that   male sex  is  risk factor  for  thyroid  
dysfunction  in HIV patients  on ART.  
Sex
FemaleMale
C
o
u
n
t
60
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20
10
0
TSH
Normal
Abnormal
 
Correlation  Between  Sex  And  TSH 
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                                         Table 4  
 CORRELATION BETWEEN SEX  AND CD4 COUNT  
  
CD4 count 
Total 
< 200 
200-
350 
> 350 
Sex 
Male Count 9 15 37 61 
% within Sex 14.8% 24.6% 60.7% 100.0% 
% within CD4 
count 
81.8% 68.2% 55.2% 61.0% 
Female Count 2 7 30 39 
% within Sex 5.1% 17.9% 76.9% 100.0% 
% within CD4 
count 
18.2% 31.8% 44.8% 39.0% 
Total Count 11 22 67 100 
% within Sex 11.0% 22.0% 67.0% 100.0% 
% within CD4 
count 
100.0% 100.0% 100.0% 100.0% 
 
 97 
CHI-SQUARE TESTS 
 
 Value Df 
Asymp. Sig.  
(2-sided) 
Pearson Chi-Square 3.421(a) 2 .181 
Likelihood Ratio 3.648 2 .161 
Linear-by-Linear Association 3.386 1 .066 
N of Valid Cases 100   
 
CORRELATION BETWEEN  SEX  AND  CD4  COUNT . 
Table 4  shows  that  low  CD4  count  up to 14.8%  are  male sex. 
Sex
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CD4 count
< 200
200-350
> 350
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TABLE 5 
 CORRELATION BETWEEN STAGE OF HIV AND TSH 
LEVEL 
   
TSH 
Total Normal 
Abnormal 
 
Stage 
I Count 67 4 71 
% within Stage 94.4% 5.6% 100.0% 
% within TSH 75.3% 36.4% 71.0% 
   
II 
Count 14 4 18 
% within Stage 77.8% 22.2% 100.0% 
% within TSH 15.7% 36.4% 18.0% 
   
III 
Count 7 3 10 
% within Stage 70.0% 30.0% 100.0% 
% within TSH 7.9% 27.3% 10.0% 
   
IV 
Count 1 0 1 
% within Stage 100.0% .0% 100.0% 
% within TSH 1.1% .0% 1.0% 
Total Count 89 11 100 
% within Stage 89.0% 11.0% 100.0% 
% within TSH 100.0% 100.0% 100.0% 
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CHI-SQUARE TESTS 
 Value Df 
Asymp. Sig.  
(2-sided) 
Pearson Chi-Square 8.215(a) 3 .042 
Likelihood Ratio 7.235 3 .065 
Linear-by-Linear Association 6.073 1 .014 
N of Valid Cases 100   
The  Table   5   shows  that   abnormal  TSH  seen  in  both  early  
and  late  stage  of disease  course. In our  study  8  patients   are  in  
stage  1&  2..  three  patients  are  stage  3.  
           RELATION BETWEEN STAGE OF HIV  AND TSH 
\
Stage
IVIIIIII
C
o
u
n
t
80
70
60
50
40
30
20
10
0
TSH
Normal
Abnormal
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TABLE 6 
   RELATION BETWEEN STAGE OF HIV AND  CD4 COUNT 
  
CD4 count 
Total 
< 200 
200-
350 
> 350 
Stage 
I Count 4 14 53 71 
% within Stage 5.6% 19.7% 74.6% 100.0% 
% within CD4 
count 
36.4% 63.6% 79.1% 71.0% 
   
II 
Count 4 5 9 18 
% within Stage 22.2% 27.8% 50.0% 100.0% 
% within CD4 
count 
36.4% 22.7% 13.4% 18.0% 
   
III 
Count 3 3 4 10 
% within Stage 30.0% 30.0% 40.0% 100.0% 
% within CD4 
count 
27.3% 13.6% 6.0% 10.0% 
   
IV 
Count 0 0 1 1 
% within Stage .0% .0% 100.0% 100.0% 
% within CD4 
count 
.0% .0% 1.5% 1.0% 
Total Count 11 22 67 100 
% within Stage 11.0% 22.0% 67.0% 100.0% 
% within CD4 
count 
100.0% 100.0% 100.0% 100.0% 
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CHI-SQUARE TESTS 
 Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 10.910(a) 6 .091 
Likelihood Ratio 10.283 6 .113 
Linear-by-Linear Association 7.103 1 .008 
N of Valid Cases 100   
Table 6  shows  that patients  with   CD4  count   above  350  are  
mostly  early  stage  [1   &  2]  ,  and   disease  progressed the  CD4  
count  falls  significantly.  
Stage
IVIIIIII
C
o
u
n
t
60
50
40
30
20
10
0
CD4 count
< 200
200-350
> 350
 
CORRELATION BETWEEN  HIV  STAGE  AND  CD4  
COUNT. 
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TABLE 7 
 RELATION BETWEEN   ART  Regimen  and  TSH 
  
TSH 
Total 
Normal Abnormal 
ART 
Regimen 
ZLN Count 72 10 82 
% within ART 
Regimen 
87.8% 12.2% 100.0% 
% within TSH 80.9% 90.9% 82.0% 
   
ZLE 
Count 16 0 16 
% within ART 
Regimen 
100.0% .0% 100.0% 
% within TSH 18.0% .0% 16.0% 
   
TLN 
Count 1 1 2 
% within ART 
Regimen 
50.0% 50.0% 100.0% 
% within TSH 1.1% 9.1% 2.0% 
Total Count 89 11 100 
% within ART 
Regimen 
89.0% 11.0% 100.0% 
% within TSH 100.0% 100.0% 100.0% 
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CHI-SQUARE TESTS 
 Value Df Asymp. Sig. (2-sided) 
Pearson Chi-Square 5.204(a) 2 .074 
Likelihood Ratio 5.720 2 .057 
Linear-by-Linear Association .020 1 .887 
N of Valid Cases 100   
Table 7  shows  that  most  of  abnormal  TSH patients   are  under  
ZLN  regimen .but  It  is  not  statistically  significant.  
ART Regimen
TLNZLEZLN
C
o
u
n
t
80
60
40
20
0
TSH
Normal
Abnormal
  
 
 
 
 
 
 
 
 
COREELATION  BETWEEN  ART  REGIMEN  AND  TSH 
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TABLE 8 
                   ART   Regimen  and  CD4  count 
Crosstab 
  
CD4 count 
Total 
< 200 
200-
350 
> 350 
ART 
Regimen 
ZLN Count 9 17 56 82 
% within 
ART 
Regimen 
11.0% 20.7% 68.3% 100.0% 
% within 
CD4 count 
81.8% 77.3% 83.6% 82.0% 
   
ZLE 
Count 1 5 10 16 
% within 
ART 
Regimen 
6.3% 31.3% 62.5% 100.0% 
% within 
CD4 count 
9.1% 22.7% 14.9% 16.0% 
   
TLN 
Count 1 0 1 2 
% within 
ART 
Regimen 
50.0% .0% 50.0% 100.0% 
% within 
CD4 count 
9.1% .0% 1.5% 2.0% 
Total Count 11 22 67 100 
% within 
ART 
Regimen 
11.0% 22.0% 67.0% 100.0% 
% within 
CD4 count 
100.0% 100.0% 100.0% 100.0% 
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CHI-SQUARE TESTS 
 Value Df Asymp. Sig. (2-sided) 
Pearson Chi-Square 4.371(a) 4 .358 
Likelihood Ratio 3.513 4 .476 
Linear-by-Linear Association .514 1 .474 
N of Valid Cases 100   
Table 8  shows that  most  of  patients  are   ZLN regimen  
[82%],  ZLE [16%], TLN [2%] … 9  patients with low  CD4 count 
are in ZLN regimen. 
ART Regimen
TLNZLEZLN
C
o
u
n
t
60
50
40
30
20
10
0
CD4 count
< 200
200-350
> 350
 
 
 
Correlation Between Cd4 Count And Art Regimen. 
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TABLE 9 
                   ART  duration  in  years  and  TSH 
  
TSH 
Total 
Normal Abnormal 
ART duration 
in years 
< 
2 
Count 27 3 30 
% within ART 
duration in years 
90.0% 10.0% 100.0% 
% within TSH 30.3% 27.3% 30.0% 
   
2-
5 
Count 54 6 60 
% within ART 
duration in years 
90.0% 10.0% 100.0% 
% within TSH 60.7% 54.5% 60.0% 
   
> 
5 
Count 8 2 10 
% within ART 
duration in years 
80.0% 20.0% 100.0% 
% within TSH 9.0% 18.2% 10.0% 
Total Count 89 11 100 
% within ART 
duration in years 
89.0% 11.0% 100.0% 
% within TSH 100.0% 100.0% 100.0% 
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CHI-SQUARE TESTS 
 Value Df Asymp. Sig. (2-sided) 
Pearson Chi-Square .919(a) 2 .632 
Likelihood Ratio .780 2 .677 
Linear-by-Linear Association .404 1 .525 
N of Valid Cases 100   
Table 9  shows  that   increasing   ART  duration  leads to more   
changes  in thyroid function.  In   our study   6  patients   with  
abnormal TSH  are   ART   duration  2 – 5 years. .but  it  is   
statistically not  significant.  
ART duration in years
> 52-5< 2
C
o
u
n
t
60
50
40
30
20
10
0
TSH
Normal
Abnormal
 
Correlation between  ART  duration and  CD4 count.  
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TABLE 10 
               ART DURATION   IN  YEARS  AND  CD4 COUNT 
Crosstab  
  
CD4 count 
Total 
< 200 
200-
350 
> 350 
ART 
duration in 
years 
< 
2 
Count 4 4 22 30 
% within 
ART duration 
in years 
13.3% 13.3% 73.3% 100.0% 
% within CD4 
count 
36.4% 18.2% 32.8% 30.0% 
   
2-
5 
Count 6 17 37 60 
% within 
ART duration 
in years 
10.0% 28.3% 61.7% 100.0% 
% within CD4 
count 
54.5% 77.3% 55.2% 60.0% 
   
> 
5 
Count 1 1 8 10 
% within 
ART duration 
in years 
10.0% 10.0% 80.0% 100.0% 
 % within CD4 
count 
9.1% 4.5% 11.9% 10.0% 
Total Count 11 22 67 100 
% within 
ART duration 
in years 
11.0% 22.0% 67.0% 100.0% 
% within CD4 
count 
100.0% 100.0% 100.0% 100.0% 
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CHI-SQUARE TESTS 
 Value Df Asymp. Sig. (2-sided) 
Pearson Chi-Square 3.671(a) 4 .452 
Likelihood Ratio 3.897 4 .420 
Linear-by-Linear Association .002 1 .961 
N of Valid Cases 100   
Table  10  shows  that  ART  duration  more  than 2 years  patients  
have  CD4  count  above  350  in most of study populatin.  
RELATION BETWEEN ART DURATION AND CD4 COUNT 
ART duration in years
> 52-5< 2
C
o
u
n
t
40
30
20
10
0
CD4 count
< 200
200-350
> 350
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DISCUSSION 
 In   this   cross  sectional   study  conducted   in   Rajiv  
Gandhi  government  general  hospital, institute  of  internal  
medicine   Chennai  over   3  month  period  from   April to  
September  among  100   adult   hiv  patients   on   anti    
retroviral  therapy. 
 The  study  group  population  subjected  to  clinical   
examination   and  biochemical  test   thyroid  profile  and  
cd4  count,  variables  are  analyzed   by   appropriate   
statistical   method. 
 The age  distribution  in our  study  group  51%  of  patients  
are  18  to  39 years,   48%  in   40  to 59   years  age  group  
and  male   sex    61%  ,   female   39%   in  this  study  
group.[Table A and  B] 
 In our  study  most  of  patients  71%   are  in  WHO  clinical  
stage 1, and  18% patients  in  stage  2,  only  10%   of  
patients  in stage 3 [Table C].  
 In  the  study  group  most  of   patients  82%   under   ZLN 
regimen,   16%   are  in  ZLE regimen[Table D],   and   60%  
patiets  on  ART   about   2  to  5 year  duration,   30%  less 
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than 2  year,  only   5%   patients   >5   year duration of    
therapy.[Table E] 
 Thyroid   dysfunction  in our  study  group   is   
o Prevalence                              -   11 % 
o Overt   hypothyroidism              -    2 % 
o Sub clinical hypothyroidism      -    9 % 
 Isolated  low  T4 level  in  our  study  group  is  4%.  
 In  Beltran  et  al   the  prevalence  of  thyroid   dysfunction  
is    
o Overt hypothyroidism  - 2.6% 
o Sub clinical hypothyroidism - 6.6% 
o Isolated low T4  level  - 6.8% 
 In  this  study  group   the  mean  values  are   
o Free   T3 -    2.106  with  SD.3290 
o Free   T4     -    1.01`2  with SD  .1896 
o Tsh             -    4.80  with  SD  14.79 
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o CD4   count     -   501.46  with  SD  262 .30 
 There  is   positive  correlation between   Free T3     and   
CD4 count   in our   study   that  is  statistically  
significant.[Table 1 ] 
o Pearson chi square                   - .000 
o Likely hood ratio                      - .002  
o Linear by linear  association - .000 
 Also  Free  T4   Positively  correlates  with   CD4 count  
which  is  statistically significant.[Table 2] 
o Pearson  chi square                  - .000 
o  Likely hood ratio                      - .006 
o Linear by linear association     - .002 
 In this  study   group , 11  patients   have  abnormal  TSH  > 
5.5,  among  these ,   8  patient    CD4 count  < 200  ,  and   1  
patient   200  - 350   ,    2  patients   are  >350. 
 Indicates   that    the  thyroid   dysfunction   common  in  
patients  with  low   CD4 count.[ Table 3]       
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 Statistically  significant   correlation  seen  in  our  study  
o Pearson chi square                  - .000 
o Likely  hood  ratio                   - .000 
o Linear by linear association - .000 
 Among  these    6  patients  are  age  group  40  to  59 years,  
and   5    18  t0  39  years .   and   8  patients  are  male,    3  
female  patients.   
 Indicates  that  thyroid  dysfunction   common  in  male  sex  
and  older  age  group. 
 Among  these  patients  with  abnormal  TSH   , 10  patients   
on   ZLN regimen,  1  patient   TLN  regimen  and   6  
patients  on  medication   2  to  5 years  duration.  
 Indicates  that   thyroid  dysfunction  common  in  patients  
with  ZLN  regimen  and   longer  duration  of  ART.  
 In these  11  patients,  stage  1  disease   4 patients,   stage  2   
in  4  patients  ,  stage   3   in  3   patients. [Table 5] 
 Indicates  that  thyroid dysfunction   common  in  both early  
and  late  stage of  disease. 
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Various  other   studies  shows  that   
 Calza   et  al    
Sub clinical hypothyroidism    12.2% 
 German   study 
Sub clinical   hypothyroidism    17.4% 
     French   study 
sub  clinical  hypothyroidism    8.5% 
overt   hypothyroidism              1.9%. 
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CONCLUSION 
 We  conclude   from   our  study  ,  there  is  increased  
prevalence  of  thyroid  dysfunction   among  HIV  infected  
patients  especially  on   anti   retro  viral  therapy.   
 There  is  significant   correlation  between   TSH  and   CD4 
count  found  in  our   study ..   TSH   negatively   correlates   
and   T3  , T4   positively   correlates   with   CD4  count.  
 The  most  patients   with  thyroid  dysfunction  are   
associated  with   low  CD4 count,  longer  duration  of   
ART,  ZLN regimen , and  in  age  group  40 -  59  years.  
 The  study  concludes  the  risk  factor for  thyroid  
dysfunction  in  HIV  patients  male  sex,  low  CD4 count,  
patient  on ART, longer  disease  course.  
 The  study  also  shows  that  the  prevalence  of  thyroid  
dysfunction  common  in  both   early  and  late  stage of  
disease.  
  By   this  study  report  that   screening  indicated  in  
symptomatic   patients and  HIV  patients   on  ART  with    
above  risk  factor.  And   screening   of   asymptomatic  HIV 
patients  recommendations  need  further   large  study.   
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          ABBREVIATIONS 
HIV Human   immuno   deficiency   virus  
AIDS Acquired   immuno   deficiency   syndrome 
HAART Highly   active   anti  retro viral  therapy 
TFT Thyroid   function   test 
TSH Thyroid   stimulating   hormone 
CMV Cytomegalovirus 
NACO National   AIDS   control   organization 
WHO World   health   organization 
MAC Mycobacterium   avium  intercellular  
complex 
ELISA Enzyme   linked  immuno  sorbent  assay 
PCR Polymerase   chain  reaction 
NNRTI Non  - Nucleoside  reverse transcriptase  
inhibitor 
NRTI Nucleoside   reverse   transcriptase   
inhibitor. 
TB Tuberculosis 
NVP Nevirapine 
TDF Tenofovir 
ATT Anti   tuberculous   therapy 
HBV Hepatitis   B   virus 
HCV Hepatitis   C   virus 
HSV Herpes   simplex virus 
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PROFORMA 
Name              :  
Age                  : 
Sex                  : 
Ip / op no    : 
Date            : 
Place           : 
SYMPTOMS QUESTIONNAIRE 
Constipation               -     + / - 
Fatigability                 -     +/- 
Weight gain                -     +/- 
Cold intolerance         -     +/- 
Heat intolerance         -      +/- 
Tremor                       -      +/- 
Weight loss                -      +/- 
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ART   regimen            - 
ART   duration          - 
WHO  stage              -      
CLINICAL EXAMINATION 
Blood    pressure   - 
Heart   rate            - 
Pallor                    - 
Thyromegaly         - 
BIOCHEMICAL PARAMETERS: 
Free     T3             - 
Free     T4            -      
Tsh                       - 
CD4  count          -                   
S. No
Hospital 
No:
Age Sex
WHO
stage
ART 
regimen
ART 
duration
dry 
skin
costipation
Cold 
intolerance
tremors
heat 
intolerance 
weight 
gain
Thromegay
Weight  
loss
Free 
T3
Free 
T4
TSH
CD4 
count
1 1285 2 1 1 1 1 1 2 2 2 2 2 2 1 1.8 1.2 1.29 244
2 3216 1 2 2 1 2 2 2 2 2 2 2 2 2 2.2 0.8 0.83 806
3 302 1 2 1 1 3 1 2 2 2 2 1 2 2 2.1 1 7.4 648
4 3759 2 1 1 1 1 1 2 2 2 2 2 2 2 2.3 1.3 1.32 513
5 2392 2 1 3 2 2 2 2 2 2 2 2 2 2 1.4 1 4.25 243
6 1427 1 2 1 1 2 2 2 2 2 2 2 2 2 2.6 0.8 2.57 608
7 3821 1 1 3 1 1 2 1 2 2 2 2 2 2 2.5 1.2 1.75 291
8 4741 2 1 2 1 2 2 2 2 2 2 2 2 1 1.9 0.78 6.97 167
9 288 1 1 2 1 3 2 2 2 2 2 2 2 2 1.8 1.4 1.74 397
10 134 1 2 1 1 3 2 2 2 2 2 2 2 2 2.3 1.2 4.25 403
11 84722 1 2 3 1 2 2 1 1 2 2 2 2 2 1.9 0.9 8.5 94
12 3362 2 2 1 1 1 2 2 2 2 2 2 2 2 2.2 1 1.47 718
13 4348 1 2 1 1 1 2 2 2 2 2 2 2 2 2.4 0.7 3.16 661
14 1447 2 1 1 2 1 2 2 2 2 2 2 2 2 2 0.85 4.75 115
15 4058 2 1 3 3 1 1 2 2 2 2 2 2 1 2.6 1.1 5.6 163
16 143/05 1 1 1 1 3 2 2 2 2 2 2 2 2 2.7 1.01 1.9 483
17 4028 1 1 1 1 1 2 2 2 2 2 2 2 1 2.8 0.88 1.71 727
18 2210 1 2 4 3 2 1 2 2 2 2 2 2 1 3.2 1.2 1.62 635
19 1733 3 1 1 2 1 2 2 2 2 2 2 2 2 2.5 1.06 2.54 509
20 2350 1 1 1 1 2 2 2 2 2 2 2 2 2 2.3 1.25 3.34 551
21 981/06 2 1 1 1 2 2 2 2 2 2 2 2 1 3.2 1.08 6.36 102
22 4221 2 1 2 1 2 2 2 2 2 2 2 2 1 2.4 0.78 1.95 116
23 1162 2 1 2 2 2 2 2 2 2 2 2 2 2 2.2 0.87 3.86 331
24 964 2 1 1 2 2 2 2 2 2 2 2 2 2 2 0.99 4.4 562
25 3432 2 1 1 2 2 2 2 2 2 2 2 2 1 1.9 0.91 1.48 1130
26 954 1 1 1 1 2 1 2 2 2 2 2 2 1 2 0.87 1.29 336
27 4135 1 1 1 1 2 2 2 2 2 2 2 2 2 2.1 0.95 4.99 697
28 2194 1 2 1 1 2 2 2 2 2 2 2 2 2 2 1.06 5.26 350
29 4263 1 1 1 1 1 2 2 2 2 2 2 2 2 1.6 0.68 4.94 86
30 4074 1 1 1 2 1 1 2 2 2 2 2 2 2 2.1 0.88 1.65 451
31 8516 1 1 2 1 1 1 2 2 2 2 2 2 1 2 0.91 6.88 143
32 92506 2 1 1 1 1 1 2 2 2 2 2 2 1 2.16 1.12 7.43 865
33 4830 2 1 1 1 1 2 2 2 2 2 2 2 2 1.9 0.86 3.41 387
34 1949 1 1 1 1 2 2 2 2 2 2 2 2 2 2 0.82 2.98 573
35 5706 1 2 1 2 2 2 2 2 2 2 2 2 2 2.6 1.05 1.42 1619
36 2719 1 2 1 1 2 2 2 2 2 2 2 2 2 2 0.76 4.68 371
S. No
Hospital 
No:
Age Sex
WHO
stage
ART 
regimen
ART 
duration
dry 
skin
costipation
Cold 
intolerance
tremors
heat 
intolerance 
weight 
gain
Thromegay
Weight  
loss
Free 
T3
Free 
T4
TSH
CD4 
count
37 4272 2 1 1 1 1 2 2 2 2 2 2 2 2 1.9 0.91 2.26 550
38 2371 2 2 1 1 2 2 2 2 2 2 2 2 2 2.4 0.83 2.08 730
39 971 1 1 1 1 2 2 2 2 2 2 2 2 2 2.2 0.95 1.71 936
40 1936 1 2 1 1 2 2 2 2 2 2 2 2 2 2.4 0.78 1.71 335
41 2318 2 1 1 1 2 2 2 2 2 2 2 2 2 1.8 0.93 3.07 505
42 3448 1 2 2 1 2 1 1 1 2 2 1 1 2 1 0.61 150 165
43 2321 1 2 1 2 1 2 2 2 2 2 2 2 2 1.9 0.77 3.09 517
44 2726 1 2 1 2 1 2 2 2 2 2 2 2 2 1.9 0.85 1.91 1278
45 2502 1 1 1 1 2 2 2 2 2 2 2 2 2 1.8 1.09 0.36 539
46 2503 1 2 1 1 2 2 2 2 2 2 2 2 2 2.1 1.06 1.66 653
47 3343 2 1 1 1 1 2 2 2 2 2 2 2 2 2.2 1.09 4.66 601
48 2691 1 2 1 1 1 2 2 2 2 2 2 2 2 2.1 1.08 1.93 855
49 3628 1 1 1 1 2 2 2 2 2 2 2 2 1 1.9 0.91 3.58 276
50 3281 1 2 1 1 2 2 2 2 2 2 2 2 2 2.2 1.07 2.73 948
51 681 2 1 1 1 2 2 2 2 2 2 2 2 2 1.9 0.96 4.49 528
52 3059 2 1 1 1 2 2 2 2 2 2 2 2 2 2 1.17 3.5 435
53 3420 1 1 1 1 1 2 2 2 2 2 2 2 2 2.2 1.25 3.5 453
54 3434 2 1 1 1 2 2 2 2 2 2 2 2 2 2 1.14 2.25 506
55 1547 1 1 1 1 2 2 2 2 2 2 2 2 2 2.4 1.25 2.38 712
56 2859 1 1 1 1 2 1 2 2 2 2 2 2 1 1.8 0.9 9.21 155
57 3308 1 1 2 1 1 2 2 2 2 2 2 2 2 2.1 1.13 1.43 336
58 2364 1 1 2 1 1 2 2 2 2 2 2 2 2 2.3 1.1 2.6 497
59 3860 2 2 3 2 1 2 2 2 2 2 2 2 2 2.4 1.2 4.5 501
60 1068 2 1 1 1 2 2 2 2 2 2 2 2 2 2.4 0.88 3.73 369
61 2077 2 1 1 1 2 2 2 2 2 2 2 2 2 2.4 0.9 2.36 559
62 1337 2 2 1 1 2 2 2 2 2 2 2 2 2 1.9 1.2 3.1 507
63 114 2 2 1 1 2 2 2 2 2 2 2 2 2 2.1 1.12 2.5 502
64 2469 1 2 1 1 2 2 2 2 2 2 2 2 2 2.2 1.3 3.25 750
65 5247 1 2 1 1 2 2 2 2 2 2 2 2 2 2 0.99 3.64 992
66 3820 1 2 1 1 1 2 2 2 2 2 2 2 1 2.4 1.01 2.95 558
67 3759 2 2 1 1 2 2 2 2 2 2 2 2 2 2 0.7 2.85 653
68 1739 1 1 2 1 1 2 2 2 2 2 2 2 2 2.6 1.25 1.43 576
69 2502 1 1 1 1 2 2 2 2 2 2 2 2 2 2 1.07 2.1 326
70 2182 2 1 1 1 2 2 2 2 2 2 2 2 2 2 1.13 2.04 226
71 3077 2 1 2 1 2 2 2 2 2 2 2 2 2 1.8 1 6.25 256
72 4786 2 1 3 1 3 1 1 2 2 2 2 1 2 1.5 0.69 12.5 164
S. No
Hospital 
No:
Age Sex
WHO
stage
ART 
regimen
ART 
duration
dry 
skin
costipation
Cold 
intolerance
tremors
heat 
intolerance 
weight 
gain
Thromegay
Weight  
loss
Free 
T3
Free 
T4
TSH
CD4 
count
73 5660 2 1 3 2 3 2 2 2 2 2 2 2 1 2.1 0.6 2.75 456
74 7831 1 2 1 1 2 2 2 2 2 2 2 2 2 2.4 1 4.49 384
75 9201 2 2 2 2 2 2 2 2 2 2 2 2 2 2.2 0.9 4.5 208
76 1810 2 1 1 1 2 2 2 2 2 2 2 2 1 1.9 0.99 3.3 226
77 2378 2 1 3 2 3 1 2 2 2 2 2 2 1 1.8 1.2 1.5 289
78 4565 2 1 1 1 2 2 2 2 2 2 2 2 1 1.9 0.96 2.25 314
79 4400 1 2 1 1 1 2 2 2 2 2 2 2 2 1.86 1.24 2.5 336
80 5491 1 1 1 1 2 2 2 2 2 2 2 2 2 1.7 0.92 3.39 467
81 3322 1 2 1 1 2 2 2 2 2 2 2 2 2 1.96 0.8 2.35 512
82 1061 1 2 2 1 2 2 2 2 2 2 2 2 2 1.84 0.89 5.2 567
83 387 2 2 2 1 2 1 2 2 2 2 2 2 2 1.94 1.2 4.48 613
84 7700 2 1 2 1 3 2 2 2 2 2 2 2 2 2.25 1.25 4.56 436
85 1745 2 1 1 1 3 2 2 2 2 2 2 2 2 2.4 1.3 3.8 520
86 7432 2 1 1 2 2 2 2 2 2 2 2 2 2 1.85 0.8 2.5 560
87 8765 2 2 2 2 2 2 2 2 2 2 2 2 2 1.9 1.2 1.25 317
88 9123 1 2 1 1 1 2 2 2 2 2 2 2 2 1.7 1.45 2.26 846
89 6987 1 1 1 1 1 1 2 2 2 2 2 2 2 1.96 0.85 3.17 870
90 4671 2 1 1 1 2 2 2 2 2 2 2 2 2 2.25 1.2 3.3 396
91 7209 2 1 2 1 2 2 2 2 2 2 2 2 2 2.4 1.36 4.5 436
92 987 2 2 3 1 3 2 2 2 2 2 2 2 2 2.32 1.4 4.26 900
93 1004 2 1 2 1 2 2 2 2 2 2 2 2 1.7 0.9 2.23 746
94 4207 2 1 1 1 2 1 2 2 2 2 2 2 2 1.99 0.96 2.73 336
95 4090 1 2 1 1 2 2 2 2 2 2 2 2 2 2.26 1.12 3.5 350
96 2333 1 2 1 1 2 2 2 2 2 2 2 2 2 2.4 0.89 2.38 342
97 4212 1 1 1 1 2 1 2 2 2 2 2 2 1 1.92 0.96 1.96 286
98 1992 2 2 1 1 2 2 2 2 2 2 2 2 2 2.23 0.98 2.1 547
99 3089 2 2 1 1 1 2 2 2 2 2 2 2 2 1.9 1.46 2.38 602
100 4781 2 1 3 1 2 2 2 2 2 2 2 2 2 1.7 0.9 3.42 740
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KEY TO MASTER CHART 
AGE   GROUP 
 18   to     39   yrs   -   1 
 40   to     59   yrs   -   2 
 > 60  yrs                -   3 
SEX 
 MALE         -    1 
 FEMALE    -    2 
WHO    CLINICAL    STAGE 
 STAGE   1  - 1   
 STAGE  2  -  2 
 STAGE  3  -  3 
 STAGE  4  -  4 
ART   DURATION 
 <   2      yrs     -   1 
  2  to 5  yrs     -   2 
 >   5      yrs     -   3 
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ART    REGIMEN 
 ZLN  -   1 
 ZLE  -    2 
 TLN  -   3 
SYMPTOMS 
 Present   -  1 
 Absent   -   2 
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INFORMATION SHEET  
TITLE: 
We  are  conducting  a  study  on “PREVALENCE OF 
THYROID DYSFUNCTION IN ADULT HIV PATIENT ON 
HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY 
IRRESPECTIVE OF STAGING & CORRELATION 
BETWEEN TSH AND CD4 COUNT” among  patients attending  
Rajiv  Gandhi  Government  General  Hospital ,Chennai  and  for  
that  your  specimen  may  be  valuable  to  us.  
NAME OF THE INVESTIGATOR:      DR.P.KARTHIK. 
THE STUDY: 
To   address   the   Thyroid   dysfunction   in  adult  hiv  
patient on highly active anti-retroviral therapy irrespective of  
staging &  correlation  between tsh and CD4 count.  
STUDY DESIGN:    Cross Sectional Study. 
STUDY PROCEDURE 
We  are  selecting  certain   cases  and  if  you  are  found  
eligible, after filling up the questionnaires ,we may be using your 
blood  samples to do special studies which Includes free T3, free 
T4, Thyroid stimulating hormone ,CD4 count. These   tests  in  
anyway do not affect your final report or management.  
POSSIBLE RISKS: 
No possible risks by means of this study.  
POSSIBLE BENEFIT 
If this study confirms the  association , therapeutic 
intervention by means of supplementation of  thyroxine can be 
considered. 
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The  privacy  of  the  patients  in  the  research  will  be  
maintained throughout the study. In  the  event of  any  publication 
or presentation resulting from the research, no personally 
identifiable information will be shared.  
Taking part in this study is voluntary. You are free to decide 
whether to participate  in this study  or to withdraw  at any time; 
your decision will not result in any loss of  benefits to which you 
are  otherwise entitled.  
The  results  of  the special study may be intimated to you at 
the end of the study  period  or  during  the  study if  anything is 
found abnormal which may aid in the management or treatment.  
 
 
Signature of Investigator   Signature of Participant  
 
Date : 
Place : 
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PATIENT CONSENT FORM 
Study Detail : “Prevalence of thyroid dysfunction in adult hiv patient 
on highly active anti-retroviral therapy irrespective of 
staging & correlation between TSH and CD4 count” 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai.  
Patient’s Name :  
Patient’s Age :  
Identification 
Number 
:  
Patient may check (√) these boxes  
a) I confirm that I have understood the purpose of procedure for the above 
study. I have the opportunity to ask question and all my questions and 
doubts have been answered to my complete satisfaction.  
b) I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time without giving reason, without my legal rights 
being affected.  
c) I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities will 
not need my permission to look at my health records, both in respect of 
current study and any further research that may be conducted in relation to 
it, even if I withdraw from the study I agree to this access. However, I 
understand that my identity will not be revealed in any information released 
to third parties or published, unless as required under the law. I agree not to 
restrict the use of any data or results that arise from this study.  
d) I agree to take part in the above study and to comply with the instructions 
given during the study and faithfully cooperate with the study team and to 
immediately inform the study staff if I suffer from any deterioration in my 
health or well being or any unexpected or unusual symptoms.  
e) I hereby consent to participate in this study.  
f) I hereby give permission to undergo complete clinical examination and 
biochemical tests.   
 
Signature/thumb impression 
Patient’s Name :  
Address:   
MuhŒ¢á jftš jhŸ 
MuhŒ¢á jiy¥ò 
v¢.I.É. nehahš ghâ¡f¥g£L k‰W« mj‰FÇa mâåÇaÄ¡f kUªJfis 
c£bfhŸS« M©fŸ k‰W« bg©fË‹ ijuhŒL Ru¥ãÆš V‰gL« 
kh‰w¤fis m¿jš k‰W« ijuhŒL cªJ Ah®nkh‹ k‰W« áo eh‹F 
msÉid x¥ãLjš g‰¿a MŒî 
MuhŒ¢áahs® bga® : bgh.fh®¤â¡ 
MuhŒ¢á ïl« : uhé›fhªâ muR bghJ kU¤Jtkid, br‹id 
g¤nf‰ghs® bga® : 
taJ : 
ghÈd« : 
MuhŒ¢áÆ‹ neh¡f« : 
v¢.I.É. nehahš ghâ¡f¥g£L, mj‰FÇa åÇaÄ¡f kUªâid 
c£bfhŸS« M©fŸ k‰W« bg©fS¡F gšntW ehsÄšyh Ru¥ãÆš 
ãu¢ridfŸ V‰glyh«, mâš ijuhŒL Ru¥ãÆš V‰gL« FiwghLfis 
m¿tnj ïªj MuhŒ¢áÆ‹ neh¡fkhF«. k‰W« ijuhŒL cªJ 
Ah®nkh‹ áo eh‹F msÉid x¥ã£L nehÆ‹ ÔÉu j‹ikia 
cz®ªJ bfhŸtJnk ïªj MuhŒ¢áÆ‹ neh¡fkhF«.  
MuhŒ¢á Kiw: 
ïªj MuhŒ¢áÆš c¤fŸ ïu¤j¤âš ijuhŒL Ru¥ãÆ‹ 
brašgh£il m¿í« gÇnrhjidí«, áo eh‹F msÉid m¿í« 
gÇnrhjidí« brŒJ jftšfis MuhŒnth«. ïj‰fhf c¤fËlÄUªJ 
5Ä.È ïu¤j« k£L« xU Kiw vL¡f¥gL« v‹gij 
bjÇÉ¤J¡bfhŸ»nwh«. 
MuhŒ¢áÆ‹ gy‹ k‰W« Ô¤F 
ïªj MuhŒ¢áÆš ijuhŒL Ru¥ãÆš V‰gL« FiwghLfŸ 
cWâbrŒa¥g£lhš, ijuh¡Ìid kUªjhf ga‹gL¤â, ijuhŒL 
Fiwgh£odhš V‰gL« ãu¢áidfis Ú¡f e‹ik cUthfyh«. ïªj 
MuhŒ¢áÆ‹ _y« g¤nf‰gt®fS¡F vªj Ô¤F« »ilahJ. Ú¤fS« 
ïªj MuhŒ¢áÆš g¤nf‰f eh¤fŸ ÉU«ò»nwh«.  
Koîfis mšyJ fU¤J¡fis btËÆL« nghnjh mšyJ 
MuhŒ¢áÆ‹ nghnjh j¤fŸ bgaiunah mšyJ milahs¤fisnah 
btËÆlkh£nlh« v‹gijí« bjÇÉ¤J¡bfhŸ»nwh«.  
ïªj áw¥ò gÇnrhjidÆ‹ Koîfis MuhŒ¢áÆ‹ nghJ mšyJ 
mj‹ KoÉš m¿É¡f¥gL« v‹gijí« bjÇÉ¤J¡bfhŸ»nwh«. ïjdhš 
j¤fsJ MŒt¿¡ifnah, m‹whl brašghLfnsh ghâ¡f¥glhJ v‹W 
bjÇÉ¤J¡bfhŸ»nwh«. 
ïªj MuhŒ¢áÆš g¤nf‰gJ j¤fSila brhªj ÉU¥g¤â‹ ngÇš 
jh‹ ïU¡»wJ. nkY« Ú¤fŸ vªj neuK« ïªj MuhŒ¢áÆÈUªJ 
ã‹th¤fyh« v‹gijí« bjÇÉ¤J¡bfhŸ»nwh«.  
 
 
MuhŒ¢áahs® ifbah¥g«   g¤nf‰ghs® ifbah¥g« 
ehŸ  :  uhé›fhªâ muR bghJ kU¤Jtkid 
ïl« : 
MuhŒ¢á x¥òjš jhŸ 
MuhŒ¢á jiy¥ò 
v¢.I.É. nehahš ghâ¡f¥g£L k‰W« mj‰FÇa mâåÇaÄ¡f kUªJfis 
c£bfhŸS« M©fŸ k‰W« bg©fË‹ ijuhŒL Ru¥ãÆš V‰gL« 
kh‰w¤fis m¿jš k‰W« ijuhŒL cªJ Ah®nkh‹ k‰W« áo eh‹F 
msÉid x¥ãLjš g‰¿a MŒî 
MuhŒ¢áahs® bga® : bgh.fh®¤â¡ 
MuhŒ¢á ïl« : uhé›fhªâ muR bghJ kU¤Jtkid, br‹id  
g¤nf‰ghs® bga® : 
taJ : 
ghÈd« : 
ïªj MuhŒ¢áÆ‹ Étu¤fS« mj‹ neh¡fK« KGikahf vd¡F 
bjËthf És¡f¥g£lJ. 
vd¡F És¡f¥g£l Éõa¤fis òÇªJbfh©L eh‹ vdJ 
r«kj¤ij bjÇÉ¡»nw‹. 
vdJ ïu¤j¤âš ijuhŒL Ru¥ãÆ‹ brašghlil m¿í« 
gÇnrhjidí«, áo eh‹F gÇnrhjidí« brŒJbfhŸs r«kj«.  
ïªj MuhŒ¢áÆš ahUila Ã®gªjÄ‹¿ brhªj ÉU¥g¤â‹ ngÇš 
r«kâ¡»nw‹. 
ïªj MuhŒ¢áÆš ïUªJ eh‹ vªj neuK« ã‹th¤fyth« 
v‹W«, mjdhš vªj ghâ¥ò« V‰glhJ v‹gijí« òÇªJ bfh©nl‹.  
eh‹ ïªj MuhŒ¢áÆ‹ Étu¤fis bfh©l jftšfis 
bg‰W¡bfh©nl‹. 
ïªj gÇnrhjid¡F vdJ clÈš ïUªJ Cá _y« 5 Ä.È ïu¤j« 
xU Kiw k£L« vL¡f r«kâ¡»nw‹. ïu¤j« vL¡F« nghJ, tÈ, ka¡f« 
ngh‹w ã‹ÉisîfŸ V‰glyh« v‹W« bjÇªJ bfh©nl‹.  
eh‹ v‹Dila Ra Ãidîl‹ k‰W« KG Rjªâu¤Jl‹ ïªj 
MuhŒ¢á¡F v‹id gÇnrhâ¡f r«kâ¡»nw‹.  
 
 
MuhŒ¢áahs® ifbah¥g«   g¤nf‰ghs® ifbah¥g« 
ehŸ  :  uhé›fhªâ muR bghJ kU¤Jtkid  
ïl« :
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